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ABSTRACT
Autophagy is an intracellular degradation system that delivers cytoplasmic components to
the lysosome for degradation. Autophagy is essential for cellular homeostasis and provides a
mechanism to adapt to metabolic and stress cues. Endothelial autophagy regulates the response of
ECs to a variety of stress factors related to EC homeostasis and plasticity. However, the precise
role of autophagy in angiogenesis requires more detailed research. Although autophagy-related 7
(ATG7) is essential for classical degradative autophagy and cell cycle regulation, whether and how
ATG7 influences endothelial cell (EC) function and regulates post-ischemic angiogenesis remain
unknown. Endothelial dysfunction is a potential contributor to the pathogenesis of diabetic
cardiovascular complications. However, little is known about disruptions of endothelial autophagy
contributing to diabetes-induced endothelial dysfunction. This dissertation aims to address how
ATG7 influences endothelial cell (EC) function and regulates post-ischemic angiogenesis, and to
determine the role of autophagy in the development of endothelial dysfunction.
EC-specific deletion of Atg7 significantly impaired angiogenesis, delayed the recovery of
blood flow reperfusion, and displayed reduction in hypoxia inducible factor 1 subunit alpha
(HIF1A) expression. Mechanistically, lack of ATG7 in the cytoplasm disrupted the association
between ATG7 and transcription factor ZNF148/ZBP-89 that is required for STAT1 (signal
transducer and activator of transcription1) constitutive expression, increased the binding between
ZNF148/ZBP-89 and importin-β1 (KPNB1), which promoted ZNF148/ZBP-89 nuclear
translocation, and increased STAT1 expression. STAT1 bond to HIF1A promotor and suppressed
HIF1A mRNA expression, thereby preventing ischemia-induced angiogenesis. These results
demonstrate that ATG7 deficiency is a novel suppressor of ischemia-induced angiogenesis.

In addition, streptozotocin (STZ)-induced type 1 diabetes inhibits autophagic flux and
reduced protein levels of autophagy gene related protein, including ULK1, ATG7, ATG5, and
Beclin1, which was accompanied by an impairment of acetylcholine-induced relaxation of isolated
mouse aortas. Inhibition of endothelial autophagy by the deletion of endothelial ULK1 exacerbated
diabetes-induced endothelial dysfunction, reactive oxygen species (ROS) overproduction and
impeded endothelial nitric oxide synthase (eNOS) phosphorylation. Mechanistically, suppression
of autophagy by diabetes aggravated ROS overproduction. Downregulation of ULK1 reduced
eNOS phosphorylation. Thus, promoting autophagy activity may be a potential strategy to prevent
endothelial dysfunction in diabetes.
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1.1

INTRODUCTION

Endothelium
The endothelium is a single layer of endothelial cells (ECs) lining the entire vascular

system (Kruger-Genge, Blocki, Franke, & Jung, 2019). Unlike smooth muscle cells, they also
cover the blood and the lymphatic capillaries. Endothelium possesses a wide range of functions,
including regulation of vascular tone, angiogenesis, thrombosis, smooth muscle cell
proliferation, and inflammatory response.
Endothelium allows molecules ranging from 0.1 nm to 11.5 nm in diameter to pass
through it (Sukriti, Tauseef, Yazbeck, & Mehta, 2014). Under physiological conditions, the
molecules smaller than 6 nm in diameter can pass passively through endothelial cell-cell
junctions, whereas the larger molecules must be transported by endocytosis of ECs. Precise
regulation of endothelial permeability is crucial for maintaining endothelial barrier function and
preventing tissue edema.
Endothelium not only serves as a barrier between vessels and tissues but also functions as
sensor to monitor the surrounding environment. In respond to shear stress and chemical stimuli,
endothelium secretes diverse molecules, among them, nitric oxide (NO) is one of the most
crucial molecules, which induces vasodilation, promotes angiogenesis, inhibits platelet
aggregation, prevents inflammatory response, inhibits smooth muscle cell proliferation, and
delivers the distress signal to different organs (Alderton, Cooper, & Knowles, 2001; Daiber et
al., 2019; Tousoulis, Kampoli, Tentolouris, Papageorgiou, & Stefanadis, 2012). Thus, NO
production is essential for maintaining endothelial homeostasis.
The evidence collected from human beings indicates that risk factors associated with
endothelial dysfunction (also called endothelial activation), including smoking, hypertension,
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hyperglycemia, hyperlipidemia, and diabetes etc., also correlates with the progression of vascular
diseases and forecasts the incidence of cardiovascular events (Deanfield, Halcox, & Rabelink,
2007; Grover-Paez & Zavalza-Gomez, 2009). Endothelial dysfunction is characterized by
switching endothelial cells from a quiescent status toward one that promotes inflammation and
coagulation. Thus, it is associated with most forms of cardiovascular disease, such as
hypertension, coronary artery disease, chronic heart failure, peripheral vascular disease, diabetes,
chronic kidney failure, and severe viral infections (Almourani, Chinnakotla, Patel,
Kurukulasuriya, & Sowers, 2019; L. Chen & Hao, 2020; Dong et al., 2019; Haffner, 2006;
Jankowski, Floege, Fliser, Bohm, & Marx, 2021; Sowers, Epstein, & Frohlich,
2001). Endothelial dysfunction precedes damaged endothelial cell integrity, senescence, and
apoptosis. The dysfunctional ECs might detach from blood vessels and be flushed into the
circulation, serving as a biomarker of endothelial dysfunction (Deanfield et al., 2007). Here, I
focus on the regulatory effects of endothelium on angiogenesis and vasodilation.

1.2

Endothelium and angiogenesis
Angiogenesis is the formation of new blood vessels from the existing vasculature. Until

recently, two forms of angiogenesis have been described, such as sprouting angiogenesis and
intussusceptive angiogenesis (Burri, Hlushchuk, & Djonov, 2004). The new blood vessel
formation supplies the tissues with oxygen and nutrients, which are critical for wound healing
and the successful treatment of cardiovascular diseases. On the other hand, tumor angiogenesis
promotes tumor growth and enables tumor cell invasion and dissemination. The basic steps of
sprouting angiogenesis include: (1) endothelial cells receive pro-angiogenic signals, resulting in
degradation of vascular basement membrane and activation of endothelial cells; (2) endothelial
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cells sprouts, proliferates, and migrates within extracellular matrix; (3) formation of lumen within
the vascular sprouts, thereby creating vascular tubes; and (4) vascular tubes are encircled by
vascular basement membrane and pericytes, thereby stabilizing the new vessels (Senger & Davis,
2011).
Intussusceptive angiogenesis is characterized by extending the capillary wall into the
lumen of an existing vessel and splitting a single vessel into two vessels. It occurs in three
distinct phases: (1) formation of contact zone between two capillary walls; (2) the ECs are
reorganized and allow cells enter the lumen; (3) the contact zone is filled by migrating pericytes
and fibroblasts, creating an extracellular matrix (ECM) network for vessel lumen formation,
subsequently it is reorganized to generate two vessels (Burri et al., 2004). Therefore, in
intussusceptive angiogenesis, new vessels develop without increasing endothelial cell
proliferation (Mentzer & Konerding, 2014). Another mechanism of new blood vessel formation
is arteriogenesis, in which pre-existent arterio-arteriolar anastomoses are remodeled into much
larger conductance artery. Unlike angiogenesis, arteriogenesis is mainly induced by physical
forces, most importantly fluid shear stress. It is characterized by an increase in the diameter of
existing arterial vessels without altering vessel number (van Royen et al., 2001).
Physiologically, angiogenesis is crucial for embryonic development, tissue and organ
growth, and normal wound healing. In pathological conditions, angiogenesis is associated with
tumor growth, invasion, and metastasis. In normal condition, a balance between angiogenic
inductors and inhibitors maintains the quiescent capillary vasculature. The major pro- and antiangiogenic factors are listed in the Table 1-1. One of the most important triggers initiating
angiogenesis is the lack of oxygen. Hypoxia stabilizes hypoxia-inducible factors (HIFs) and
prevents its degradation, resulting in the accumulation of HIFs, which sequentially activates

RUNNING HEAD
4
transcription of a variety of genes encoding proteins involved in regulating each step of
angiogenesis (Semenza, 2003).

Table 1.1 Partially listed factors implicated in angiogenesis
Stimulator
Mechanism
Shear stress

Initiation of angiogenesis (Wragg et al., 2014)

Exercise

Capillaries increased and enlarged (Gorski & De Bock,
2019)
Increase permeability, devastating extracellular matrix,
promote EC proliferation, migration, and survival
(Przybylski, 2009)
Promote VEGF, transforming growth factor-β3 expression

VEGF

HIF1A
FGF
VEGFR and NRP
peroxisome-proliferatoractivated receptor-γ
coactivator-1α (PGC-1α)
Ang1 and Tie2

Stimulate ECs proliferation, migration and extracellular
matrix rearrangement (Przybylski, 2009)
Transducer of survival signals, expressed on endothelial
tip cells and guide tip cells
Induce VEGF expression by HIF independent pathway
(Arany et al., 2008)

Integrins

Stabilize vessels, prim bone marrow-derived progenitor
cells, increase adhesion molecule production
Induce new vessel formation, mature neovascularized
vessels by recruiting smooth muscle cells
Increase extracellular matrix components expression,
activate EC proliferation and migration, active growth
factors (Pardali & ten Dijke, 2009)
Activate monocytes and promote VEGF expression
(Pardali and ten Dijke 2009)
Bind matrix macromolecules and proteinases

VE-cadherin and CD31

Endothelial junctional molecules

ephrin

Determine formation of arteries or veins

plasminogen activators

Nogo-A

remodels extracellular matrix, releases and activates
growth factors
Retain tumor-associated macrophage in hypoxia, promote
EC survival (B. Jiao et al., 2021)
Promote vasculature formation in the insult of stroke

MMPs

Facilitate matrix degradation, activate integrin

Placental growth factor
(PLGF)

Stimulate EC growth and migration, recruit and activate
monocytes (Carmeliet & Jain, 2011)

PDGF and PDGFR
TGF-β and TGF-β
receptors
CCL2

SEMA3A, 3B, 3C
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Integrin
Inhibitor
Thrombospondin-1
(TSP-1)
Epigallocatechin-3gallate
Angiostatin
Endostatin
Vasostatin
Tumstatin
Arresten, Canstatin
MMP inhibitors
IFN-α, β, γ
SEMA3A, 3B, 3C, 3E,
3F
Nogo-A

Facilitate EC migration and survival(Avraamides, GarmySusini, & Varner, 2008)
Mechanism
Antagonize of VEGF(Hanahan & Folkman, 1996; P. R.
Lawler & Lawler, 2012) (Hanahan & Folkman, 1996)
Inhibit MMP-2, prevent EC invasion and growth (Cao &
Cao, 1999)
Inhibit EC proliferation, promote EC apoptosis
Inhibit EC proliferation, promote EC apoptosis
Inhibit EC attachment to laminin (Ribatti, 2009), inhibit of
VEGFR signaling (Wei et al., 2021)
Inhibit activation of focal adhesion kinase, inhibitEC
protein synthesis (Yamamoto et al., 2004)
Inhibit EC proliferation, migration, inhibit integrin/focal
adhesion kinase (FAK) and Akt signaling pathway
Inhibit EC migration and proliferation
Inhibit FGF, inhibit MMPs, induce cell apoptosis
Inhibit VEGF secretion or signaling pathways, destruct
integrin-related adhesion, prohibit EC proliferation,
migration and sprouting (B. Jiao et al., 2021)
Inhibited spreading, migration, and sprouting of primary
brain microvascular ECs, retract lamellipodia and
filopodia in developmental CNS (Walchli et al., 2013)

In adult individuals, the endogenous angiogenesis inhibitors counteract pro-angiogenic
signals and prevent new vessel formation. Angiogenesis occurs when the total angiogenic
stimulation overwhelms the total angiogenic inhibition, conversely, angiogenesis is inhibited
once pro-angiogenic factors are overcame by anti-angiogenic ones. Correspondingly, enhanced
angiogenesis ensures blood supply to all cells within an organ, whereas impaired angiogenesis
diminishes blood flow.
The imbalance between pro-angiogenesis and anti-angiogenesis factors in implicated in
cancer and various ischemic and inflammatory diseases. For example, cancer and age-related
macular degeneration are characterized by excessive angiogenesis. In contrast, reduced
angiogenic activity leads to ischemia and worsens the prognosis in patients with cardiac
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infarction and peripheral artery occlusions. Recent progress in understanding the roles of
extracellular matrix remodeling and ECs metabolic adaptation in angiogenesis makes
them attractive anti-angiogenic targets. Pathological shear stress reduces the expression of
extracellular matrix proteins, including glycosaminoglycans and proteoglycans, potentiating
angiogenesis (Russo, Banuth, Nader, & Dreyfuss, 2020). Further study shows that shear stress
above the 10 dyn/cm2 induces sprouting angiogenesis specifically up-regulates the expression of
matrix metallopeptidase 1 (MMP1) (Galie et al., 2014), which breaks down the extracellular
matrix and is important in step 1 of angiogenesis. ECs produces ATP relying on glycolysis rather
than on oxidative phosphorylation, which is required for angiogenesis, inhibition of glycolysis in
ECs impairs vessel formation (De Bock et al., 2013). By comparing murine choroidal ECs with
choroidal neovascularization ECs, researchers find that two genes, Aldh18a1 and Sqle, encoding
pyrroline-5-carboxylate-synthetase (P5CS) and squalene monooxygenase respectively, have
higher expression in choroidal neovascularization ECs. P5CS is the key enzyme that catalyzes
synthesis of proline from glutamate, while squalene monooxygenase is a rate-limiting enzyme
responsible for cholesterol synthesis (Rohlenova et al., 2020). Thus, the regulation of glycolysis
and extracellular matrix (ECM) degradation and remodeling plays a critical role in controlling
new vessel formation, stabilization, and maturation.
1.2.1

Angiogenesis in cancers

Angiogenesis occurs before a tumor can grow to larger than 1-2 mm in size. Unlike the
temporary activation of angiogenesis in wound healing and menstrual cycle, the angiogenesis
activation in cancer seems to be permanent. During tumor angiogenesis, overexpression of proangiogenic factors leads to the development of disorganized blood vessel networks. Tumor
vasculature is characterized by hemorrhage, hyper-permeability, and disorganized branching
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(Schaaf, Garg, & Agostinis, 2018). The abnormality of angiogenesis in tumors contribute to
the formation of an acidic microenvironment due to the inefficiency in removing metabolic
wastes, such as carbon dioxide and lactic acid (Nagy, Chang, Shih, Dvorak, & Dvorak, 2010).
In response to the increased requirement of nutrients and oxygen, tumor cells or stroma
cells release angiogenic molecules, such as VEGF-A, that contribute to formation of new
vasculature. In solid tumor, the hypoxic environment is considered as the major stimulators of
VEGF expression. Additionally, other mechanisms may also participate in regulation of VEGFA generation, such as expression of oncogenes, deletion of tumor suppressor genes, and
stimulation by either cytokines or hormones (Palazon et al., 2017). Since VEGF-A is a wellknown HIF1A target that is up-regulated under hypoxic conditions in solid tumors, HIF1A has
been highly appreciated in tumor progression, and treatment of tumor by targeting HIF1A
warrants further studied.
1.2.2

Angiogenesis in ischemic cardiovascular diseases

Coronary artery disease (CAD) is the leading cause of death in the United States, killing
382,820 in 2020, about one in every ten deaths was due to CAD (Tsao et al., 2022).
Atherosclerosis is the primary cause of CAD, in which the plaque formation in the wall of
arteries narrows the arteries, leading to myocardial ischemia and impairing cardiac function
(Benjamin et al., 2017).
The inflammatory response following myocardial ischemia is the first stage of repairing
the infarcted myocardium, which is followed by myofibroblast activation and proliferation
(Prabhu & Frangogiannis, 2016). During this cardiac repair period, inflammatory macrophages
convert to an anti-inflammatory phenotype that reduces the production of inflammatory
mediators, including IL-10, and transforming growth factor (TGF)-β, thereby promoting fibrosis
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and angiogenesis (Hanna & Frangogiannis, 2019; Sziksz et al., 2015). This anti-inflammatory
response can extend for a long time until the adverse signaling diminishes.
Current therapeutic strategies for CAD primarily focus on the development of antiplatelet
agents, β-blockers, and statins. Besides treatment with drugs, restoring circulation to the affected
heart muscle could be achieved by surgical interventions, including coronary artery bypass graft
surgery and percutaneous coronary intervention. Unfortunately, some patients deem unsuitable to
be treated with surgical interventions. For this group of patients, promoting angiogenesis seems
to be a potential therapeutic strategy.
1.2.3

Angiogenesis in other diseases

Pathologic ocular angiogenesis occurs in many ocular disorders, including diabetic
retinopathy, retinopathy of prematurity, and age-related macular degeneration, which constitutes
most of the blindness in developed countries (Hartnett, 2014; Rajappa, Saxena, & Kaur, 2010).
Thus, anti-angiogenic therapy has opened new possibilities for the prevention of visual
impairment and blindness.
There were 236.62 million people older than 25 years suffered from peripheral artery
diseases (PAD) worldwide in 2015. PAD is typically caused by atherosclerotic obstructions in
the large arteries to the leg(s). Increasing evidence indicates that the leading risk factors for PAD
include smoking, diabetes, hypertension, and hypercholesterolemia (Song et al., 2019). Diabetic
patients have a greater incidence and severity of PAD, which is associated with 5 to 10 times
more likely to undergo an amputation than nondiabetic individuals (Society for Vascular Surgery
Lower Extremity Guidelines Writing et al., 2015). The prevalence of PAD tends to increase in
the near future as 65-and-older population grows rapidly, obesity has become an epidemic, and
a diabetes epidemic is underway, thus, PAD has become a serious health problem worldwide.
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(Society for Vascular Surgery Lower Extremity Guidelines Writing et al., 2015) The patients
with PAD have chronic lower extremity ischemia and manifest with no symptoms or
claudication because of a severe blockage in the arteries of the lower extremities, which
markedly reduces blood flow. Currently, medical therapies used to treat patients with PAD
include lower cholesterol, antiplatelet, anticoagulation, and anti-hypertension. If these medical
management is not suitable or effective in severe cases of PAD, endovascular and surgical
interventions may be necessary. In addition to medical and interventional treatments, therapeutic
angiogenesis is a novel therapy for PAD.
In addition, angiogenesis also plays a critical role in the pathogenesis of rheumatoid
arthritis (RA). During RA, newly formed blood vessels transport inflammatory cells to the
inflammatory joints and provide oxygen and nutrients to the inflamed tissue (Elshabrawy et al.,
2015). Targeting angiogenesis in rheumatoid arthritis ameliorates symptoms. Thus, the blockade
of angiogenesis appears to be a promising therapeutic strategy for rheumatoid arthritis
1.2.4

Angiogenesis-targeted treatments

VEGF inhibitor, bevacizumab, is the first antiangiogenic agent approved by FDA in 2004
(Ferrara, Hillan, Gerber, & Novotny, 2004). Due to the key role of angiogenesis in tumor growth
and ocular diseases, numerous research groups have been engaged in the development of antiangiogenic medications, and more angiogenesis inhibitors have been approved in the treatment
of various cancers or age-related macular degeneration. Angiogenesis inhibitors may be used as
either alone or in combination with other canonical anti-cancer medicines (Table 1-2).
Preclinical and early clinical data suggest antiangiogenic reagents in combination with
chemotherapy appear to be more effective therapies for patients with cancer. On the other hand,
therapeutic angiogenesis for treatment of ischemic cardiac disease is still in its infancy.
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Stimulation of new vessel growth by VEGF to compensate for tissue ischemia, remains an
unfulfilled promise, although various approaches have been used to deliver VEGF to the
ischemic myocardium to promote angiogenesis in ischemic cardiac diseases.
1.2.4.1 Pro-angiogenesis reagents
The concept of using growth factors as a therapeutic strategy for pro-angiogenesis
evolved from the pioneering work by Folkman and colleagues in 1971 (Takeshita et al., 1994).
The first clinical trial on patients with coronary artery diseases using pro-angiogenesis therapy
was performed in Germany by targeting the patients with fibroblast growth factor 1 (FGF-1)
(Stegmann, 1998). Currently, most studies focus on direct delivery of either angiogenic growth
factors (eg. VEGF) or stem cells/progenitor cells to ischemic tissues.
Administration of VEGF-165 in rabbits undergone femoral artery ligation promotes the
regeneration of collateral vessels and capillaries, which suggests that the single administration of
VEGF is sufficiency to inducing angiogenesis (Takeshita et al., 1994; Tekabe et al., 2015).
Angiogenesis is a complex and multi-stage process. To ensure that developing or healing
tissues receive an adequate supply of nutrients, pro-angiogenesis applications should generate a
vasculature with normal structure and functions, and avoid unpropitious effects, such as
excessive vessel growth, tortuous and dilated vessels, and hyperpermeability. Thus, identify the
medicine and establishing the timing to induce angiogenesis is essential for the development of
future and more effective therapies for ischemic heart disease.
Another promising strategy for treatment of ischemic diseases is to inhibit the production
of anti-angiogenetic factors. As a potent endogenous inhibitors of angiogenesis,
thrombospondin-1 (TSP-1) expression strongly increases during myocardial infarction,
indicating an important role for TSP-1 in cardiac remodeling (Taraboletti, Rusnati, Ragona, &
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Colombo, 2010).TSP-1 inhibits angiogenesis by inhibiting endothelial cell migration and
proliferation, stimulating endothelial cell apoptosis, and antagonizing the activity of
VEGF. Previous study shows that downregulation of TSP-1 ECs enhances angiogenesis in
cultured cells, suggesting that TSP-1 may become potential therapeutic targets (J. Lawler, 2022).
In addition, in the comparison with non- diabetic patients with coronary artery disease exhibit
higher levels of anti-angiogenic factors, including angiostatin and endostatin, which inhibit
coronary collateralization. This finding suggests new therapeutic targets for proangiogenic
therapy in diabetes (Sodha et al., 2009).
1.2.4.2 Anti-angiogenesis medications
In 1971, Surgeon Judah Folkman proposed the concept that tumor growth and metastasis
are dependent on angiogenesis and inhibition of angiogenesis might be a potential therapeutic
strategy for cancer. Currently, clinical efforts to develop antiangiogenic therapies mainly focus
on multiple growth factors, receptors, and intracellular signaling pathways. Since tumor growth
requires increased new vessel formation, inhibiting angiogenesis by antiangiogenic drugs
prevents tumor progression. However, the inhibitory effect of antiangiogenic drugs on
angiogenesis can only persist for a limited time, and consequently tumors become resistant to
antiangiogenic therapy, or reoccurs after retraction of anti-angiogenesis reagents. Given that the
hypoxic tumor microenvironment stimulates tumor cells to express many growth factors,
including VEGF, FGF, and PIFG, to confront the adverse environment, and enhances new vessel
formation by bone marrow-derived stem cells (Carmeliet and Jain 2011). (Lee, Miwa et al. 2022)
Targeting single growth factor might not be able to get a satisfactory outcome in tumor
treatment.

RUNNING HEAD
12
Hypoxia-inducible factor-1 (HIF-1) has been recognized as a target for cancer therapy
because it acts as the upstream of multiple genes encoding angiogenic growth factors and
cytokines, including VEGF, erythropoietin (EPO), stromal-derived factor 1 (SDF-1), placental
growth factor (PLGF), angiopoietin 1 and 2, and platelet-derived growth factor B (PDGFB)
(Hirota & Semenza, 2006; Masoud & Li, 2015). Thus, targeting HIF-1 has attracted a lot of
attention in the development of anti-angiogenesis treatment. The regulation of HIF activity
is tightly modulated at multiple levels, such as regulation of HIF1A synthesis, HIF1A stability,
and HIF1A transactivation. Although it is well documented that the regulation of
HIF1A expression is mainly at the protein level by post-translational modifications and
degradation, increasing evidence shows that regulation of HIF1A expression at the mRNA level
by transcription factors is a rate-limiting step in modulating HIF1-A protein expression
(Chamboredon et al., 2011). Recent study suggests that an antisense oligonucleotide targeted to
HIF1A mRNA inhibits HIF1A mRNA transcription, downregulates HIF1A protein expression,
suppresses angiogenesis and tumor growth. Indeed, EZN-2968, a new type of anti-cancer drug,
composed of third-generation oligonucleotide, can specifically inhibits the expression of HIF1A
mRNA, resulting in inhibition of angiogenesis, tumor cell proliferation, and tumor growth
(Onnis, Rapisarda, & Melillo, 2009; J. Wu et al., 2019).
Antiangiogenic reagents approved by FDA are listed in Table 1-2.
Table 1.2 Antiangiogenic reagents approved by FDA
Anti-angiogenic
Indication
agent
Aflibercept
Metastatic colorectal carcinoma, wet
macular degeneration, diabetic
retinopathy
Axitinib
Renal cell carcinoma

Target
VEGF-A, VEGF-B,
PlGF
VEGFR1-3
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Bevacizumab

Cabozantinib

Everolimus

Lenalidomide

Lenvatinib mesylate

Pazopanib
Ramucirumab

Regorafenib

Sorafenib

Cervical cancer, colorectal cancer,
glioblastoma, hepatocellular
carcinoma,
nonsquamous non-small cell lung
cancer, ovarian epithelial, fallopian
tube,
primary peritoneal cancer, renal cell
carcinoma
Differentiated thyroid cancer,
hepatocellular carcinoma, medullary
thyroid
cancer, renal cell carcinoma
Breast cancer, pancreatic cancer,
gastrointestinal cancer, renal cell
carcinoma,
subependymal giant cell astrocytoma
Anemia, follicular lymphoma, mantle
cell lymphoma, marginal zone
lymphoma, multiple myeloma
Endometrial carcinoma,
hepatocellular carcinoma, renal cell
carcinoma,
thyroid cancer
Renal cell cancer, soft tissue sarcoma
Colorectal cancer, hepatocellular
carcinoma, non-small cell lung
cancer, stomach adenocarcinoma,
gastroesophageal junction
adenocarcinoma
Colorectal cancer, gastrointestinal
stromal tumor, hepatocellular
carcinoma
Hepatocellular carcinoma, thyroid
cancer, renal cell cancer
Gastrointestinal stromal tumor,
pancreatic cancer, renal cell
carcinoma

VEGF-A

MET (hepatocyte
growth factor
receptor), VEGFR
mTORC1, VEGFR-2
(Piguet et al., 2014)

HIF1A (L. Lu et al.,
2009)
VEGFR2

VEGFR1-3, PDGFR,
c-Kit
VEGFR2

VEGFR2, VEGFR3,
PDGFR, Raf, Tet, Kit

Thalidomide

Multiple myeloma

VEGFR2, PDGFR,
Raf
VEGFR2, PDGFR-β,
c-Kit, Fms-related
tyrosine kinase 3
(FLT3)
TNF-α

Vandetanib

Medullary thyroid carcinoma

VEGFR2, EGFR

Ziv-aflibercept

Colorectal cancer

VEGFR

Sunitinib
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1.3

Diabetes and endothelial dysfunction
Diabetes is a chronic metabolic disease characterized by higher blood glucose levels and

is closely associated with increased cardiovascular morbidity and mortality. There are two main
forms of diabetes, type 1 (insulin-dependent diabetes mellitus) and type 2 (non-insulin-dependent
diabetes mellitus). Type 2 diabetes is far more common than type 1 diabetes. Currently, around
90% of all adults with diabetes have type 2 diabetes. The International Diabetes
Federation reports that the prevalence of diabetes in adult was estimated to be 537 million in
2021 worldwide (Y. Yan et al., 2022). The major complications of diabetes encompass heart
attack, stroke, kidney disease, neuropathy, retinopathy, and lower-extremity amputation (Tao,
Shi, & Zhao, 2015). Poorly controlled diabetes substantially increases the risk of diabetic
complications and premature death.
Hypertension is more common in diabetic patients, and both diabetes and hypertension
share similar etiology and pathologic processes, including obesity, inflammation, oxidative
stress, and insulin resistance (Cheung & Li, 2012). Substantial clinical and experimental
evidence suggest that diabetes causes endothelial dysfunction, which reduces release or
availability of nitric oxide (NO), leading to impaired endothelium-dependent vascular relaxation
(De Vriese, Verbeuren, Van de Voorde, Lameire, & Vanhoutte, 2000). Therefore, endothelial
dysfunction has a close inter-relationship with hypertension in diabetes. Currently, it is wildly
acknowledged that diabetes increases ROS release, which leads to endothelial dysfunction.
Under diabetic conditions, there are several sources of ROS in cells, including nonenzymatic
glycosylation reaction (Nowotny, Jung, Hohn, Weber, & Grune, 2015), electron transport chain
in mitochondria (R. Z. Zhao, Jiang, Zhang, & Yu, 2019), membrane-bound NADPH oxidase
(NOX) (Laddha & Kulkarni, 2020), nitric oxide synthases, xanthine oxidases, lipoxygenases,
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cyclooxygenases, and peroxidase (Newsholme, Cruzat, Keane, Carlessi, & de Bittencourt, 2016;
Newsholme et al., 2007).
NOXs are ROS-generating enzymes. Endothelial cells express four NOX isoforms,
including the superoxide-generating enzymes NOX1, NOX2, and NOX5 and the hydrogen
peroxide-generating enzyme NOX4 (Drummond & Sobey, 2014). Hyperglycemia enhances
NOX level and activates the enzyme (Drummond & Sobey, 2014). The active NOX complex
allows for the transfer of electrons to molecular oxygen to generate superoxide, but it is still not
clear which isoform of NOX plays the leading role in hyperglycemia-induced ROS production.
The mitochondrial respiratory chain is another major source of ROS production. Under diabetic
conditions, the electron transport chain is activated to increase electron leak, which leads to
production of larger amounts of ROS (Nishikawa & Araki, 2007).
Metabolic modifications are also implicated in the development of high glucose-induced
ECs dysfunction. Hyperglycemia increases blood glucose level and inhibits glucose-6-phosphate
dehydrogenase (G6PDH) activation by promoting cAMP-PKA phosphorylation, which causes
pentose phosphate pathway (PPP) deviation and decreases NADPH levels (Z. Zhang, Apse,
Pang, & Stanton, 2000). This mechanism in turn regulates ROS production through NOX
catalyzation. It is proposed that glyceraldehyde-3-phosphate dehydrogenase (GAPDH) ADPribosylation blocks the conversion of glyceraldehyde-3-phosphate to 1,3-bisphosphoglycerate,
which inhibits physical glycolytic pathway and induces upstream metabolites accumulation (J.
Wu, Jin, Zheng, & Yan, 2016). There is almost 30% of glucose swerved to polyol pathway as the
shutting down of glycolysis (L. J. Yan, 2018). In STZ-injected rat lung, polyol pathway is
activated to replace glycolytic pathway. The activation of the polyol pathway induces the
accumulation of sorbitol and fructose content, decreases the NADPH/NADP+ ratio and nitric
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oxide production, and increases NADH/NAD+ ratio leading to ROS production and oxidative
stress (J. Wu et al., 2016; L. J. Yan, 2018). These events cause endothelial dysfunction,
consequently, accelerates diabetic vascular complications.
1.3.1

The role of ROS in endothelial injury

In general, potential sources of ROS production in ECs include NOX, xanthine oxidase,
mitochondria and uncoupled eNOS. As the byproduct of mitochondrial aerobic respiration, ROS
production is inevitable and ubiquitous in living creatures. Simultaneously, antioxidant enzymes
convert ROS into H2O2 and finally generating H2O and O2 to prevent the detrimental effects of
ROS. Thus, elaborate balancing the production and elimination of ROS is crucial for maintaining
normal biological functions in ECs. NOX is a membrane bound enzyme complex participating in
the reaction of electron transfer from NADPH to oxygen molecule to produce O2-, and H2O2.
ECs contains several isoforms of NOX, including NOX1, 2, 4, and 5 isoforms. NOX1, 2, 5
mainly produce O2-, while NOX4 predominantly catalyzes H2O2 production.
Hyperglycemia is a major stimulus of endothelial NOX activation. In several Type 2
diabetes and insulin-resistant animal models, NOX1 and/or NOX2 are demonstrated as key
generators of ROS in ECs and responsible for vascular dysfunction. High fat diet triggers NOX2
protein expression in aorta, whereas the deletion of NOX2 prevents diabetic-initiated ROS
production and endothelial dysfunction (Drummond & Sobey, 2014; Lynch et al., 2013).
In contrast to the discoveries in type 2 diabetic animal models, NOX2 inhibition does not
prevent ROS overproduction and endothelial dysfunction in STZ-treated type 1 diabetic animals.
Moreover, NOX4 seems not to be important in type 1 diabetes-induced endothelial dysfunction,
because deletion of NOX4 does not prevent artherogenesis in response to oxidative stress. By
contrast, in cultured human retinal ECs and HUVECs, NOX4 may be an important source of
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ROS and contributes to high glucose-induced endothelial dysfunction, because in high
glucose-treated cells, NOX4 expression is upregulated, and inhibition of NOX4 significantly
reduces ROS production and cell death (W. Jiao et al., 2019; Luo et al., 2019). However, NOX1
may play an essential role in the development of endothelial dysfunction in STZ-induced type 1
diabetes as NOX1 is upregulated in STZ-treated mice, which enhances ROS production and
promotes eNOS uncoupling. Suppression of NOX1 improves endothelial function in STZinduced type 1 diabetic mice (Youn, Gao, & Cai, 2012).
1.3.2

ENOS and endothelial homeostasis in diabetes

Nitric oxide (NO), a free-diffused gaseous and lipophilic molecule, is predominantly
generated from the endothelial isoform of NO synthase (eNOS), also known as nitric oxide
synthase 3 (NOS3) or constitutive NOS (cNOS), in normal condition, and is firstly identified as
endothelium-generated factor for vasorelaxation (Deanfield et al., 2007). The biological effects
of NO are involved in diverse cellular processes, including maintenance of vascular tone,
angiogenesis, tissue remodeling, and anti-inflammation (Kruger-Genge et al., 2019). The
production of eNOS and NO is stimulated by many factors, such as shear stress, insulin, and
inflammatory cytokines (Michel & Vanhoutte, 2010). In response to the changes in metabolic
demands and oxygen consumption rate, endothelium finely tunes vascular tension by release
several vasoactive modulators, such as bradykinin and thrombin. For example, when cardiac
output changes, endothelium produces vasoactive modulators to regulate vasoconstriction and
vasodilation, thus maintaining normal blood pressure (Sandoo, van Zanten, Metsios, Carroll, &
Kitas, 2010).
NO formation starts from converting L-arginine into NO and L-citrulline, which requires
core enzyme, endothelial nitric oxide synthase (eNOS). ENOS is a dimer containing two
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identical monomers. ENOS monomer is inactive, and the dimeric form is required for its
function. Monomer eNOS is composed of a reductase domain and an oxidase domain. These two
domains are bridged by a calmodulin-binding sequence. The reductase domain is the binding site
for nicotinamide adenine dinucleotide phosphate (NADPH), flavin mononucleotide (FMN), and
flavin adenine dinucleotide (FAD), while the oxidase domain contains the interacting sites for
heme group, zinc, the cofactor tetrahydrobiopterin (BH4), and the substrate L-arginine (Alp &
Channon, 2004). The bioavailability of L-arginine and enzymatic activity is responsible for NO
production, while ROS are major determinants of NO degradation. The cofactor BH4 is a
cofactor required for the synthesis of NO by eNOS (Alp & Channon, 2004). In the isolated rat
heart, ischemia decreased BH4 content, and concurrently inhibits eNOS activity, resulting
endothelial dysfunction. Administration of BH4 prevents endothelial dysfunction and improve
cardiac function in ischemia stimulation (Cai, Khoo, Mussa, Alp, & Channon, 2005; Dumitrescu
et al., 2007).
It is reported that eNOS activity is impaired in diabetic patients, because hyperglycemia
downregulates eNOS expression, inhibits eNOS phosphorylation, increases oxidation of nitric
oxide, and reduces BH4. ENOS expression is not always well correlated with the amount of NO
production (C. Heiss, Rodriguez-Mateos, & Kelm, 2015). As constitutive endothelial
overexpression of eNOS in apolipoprotein E (apoE) knockout mice reduces NO production, in
association with increased oxidative stress (Ozaki et al., 2002). Conversely, reduction of NO is
not certainly resulted from the loss of eNOS protein. Thus, regulation of NO production is
complex, it is not only regulated by eNOS expression, but also modulated by eNOS substrate and
cofactors, the phosphorylation status of eNOS, and ROS that can inactivate eNOS. Under
pathological conditions, eNOS may become dysfunctional, which generates superoxide anion
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instead of NO. This phenomenon is referred to as eNOS uncoupling that remarkably increases in
the ratio of eNOS monomers to dimers.
During pathological conditions, overproduction of ROS reduces BH4 levels by
converting it into BH3• radical leading to eNOS uncoupling. Uncoupled eNOS transfers
electrons to O2 instead of NO, resulting in generation of superoxide that can react with NO,
consequently reducing cellular NO availability by converting NO to peroxynitrite (ONOO−).
Furthermore, peroxynitrite directly promotes eNOS uncoupling. In human aortic ECs, high
glucose activates activator protein 1 (AP-1) by inducing ROS overproduction, which in turn
inhibits eNOS mRNA transcription, and consequently downregulates the eNOS protein and
inhibits its activity. In porcine aortic ECs, hypoxia-induced metabolic changes elevate
NAD(P)H/NAD(P) ratio, which activates AP-1, leading to elevation of eNOS mRNA
transcription (Hoffmann, Gloe, & Pohl, 2001).
In addition, eNOS activity is regulated by multiple sites of phosphorylation through
different signaling pathways. For example, phosphorylation of eNOS at Ser 1179 and
dephosphorylation at Thr 497 activates the enzyme, whereas phosphorylation at Thr 497 and
dephosphorylation at Ser 1179 inactivates eNOS (E. H. Heiss & Dirsch, 2014). Low share stress
inhibits eNOS activity depends on phosphorylation of eNOS-Thr495 via an ERK1/2 mechanism
(X. Kong et al., 2017), and metabolic disorders in db/db mice diminishes eNOS phosphorylation
at Ser1176 and inhibits its activity (Cheang et al., 2011). Thus, endothelial dysfunction occurring
in diabetes contributes to diabetic complications, suggesting that the endothelium is a potential
target for the therapy of diabetic cardiovascular complications.
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1.4

Autophagy
1.4.1

Overview

Autophagy, meaning self-eating, is a cellular degradation process, in which cytoplasmic
constituents are sequestered into double-membrane vesicles termed autophagosomes, and
delivered to the lysosome for breakdown. Autophagy has been divided into three general types
that are macroautophagy, microautophagy, and chaperone-mediated autophagy (CMA) (Parzych
& Klionsky, 2014). The term “autophagy” usually refers to macroautophagy. Under normal
conditions, basal-level autophagy is very low and functions as a cellular quality control
mechanism to turnover intracellular components and maintain cellular energetic balance and
serves as a stress adaptation pathway that promotes cell survival. Thus, basal autophagy might
play a protective role in many fundamental physiological processes, including development,
differentiation, and tissue remodeling. While malfunction of autophagy might contribute to the
development of many diseases including neurodegeneration, cardiovascular diseases, liver
disease, diabetes, and cancer. Autophagy consists of several sequential steps: (1) induction by an
autophagic stimulator, (2) double membrane isolation or phagophore assembly, (3) expansion
and sealing the double membrane structure to develop an autophagosome, (4) fusion the
autophagosome with lysosome to form autolysosome, and (5) degradation and recirculation of
autophagosome contents (Mizushima, 2007; Nakatogawa, 2020).
The molecular machinery of autophagy has been identified in both yeast and mammals,
and more than 40 genes encoding components of autophagy machinery, named autophagyrelated genes (ATGs), have been identified (Mizushima, 2020; Yin, Pascual, & Klionsky, 2016).
In mammalian cells, autophagy induction is controlled by the serine/threonine protein kinase
ULK1 (unc-51-like kinase 1, a homologue of yeast ATG1) complex, which is comprised of
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ULK1, ATG13, RB1-inducible coiled-coil protein 1 (RB1CC1, also known as FIP200) and
ATG101. ULK1 is directly regulated by nutrient and energy sensors MTORC1 (mechanistic
target of rapamycin complex 1) and AMPK (AMP activated protein kinase). MTORC1 is an
inhibitor of autophagy in mammalian cells. Under nutrient rich environment, MTORC1 interacts,
phosphorylates, and inactivates ULK1 and ATG13 to suppress autophagy. In contrast to
phosphorylation by MTORC1, AMPK-mediated phosphorylation of ULK1 activates ULK1 to
induce autophagy (Kim, Kundu, Viollet, & Guan, 2011). Upon ULK1 activation, the ULK1
complexes translocate to the phagophore assembly site (PAS) to trigger the nucleation of the
phagophore by phosphorylating and activating class III phosphatidylinositol 3 kinase (PI3KC3)
complexes. The PI3K complex consists of VPS34 (vacuolar protein sorting 34), Beclin1, VPS15,
and Atg14L (Atg14-like), and is responsible for the production of the phospholipid
phosphatidylinositol 3-phosphate (PtdI3P) and the recruitment of two ubiquitin-like (Ubl)
conjugation systems, Atg12-Atg5-Atg16 and Atg8-PE (phosphatidylethanolamine), to the PAS
(Suzuki et al., 2001), which are important in regulating the membrane nucleation process and
autophagosome formation.
The expansion of the isolation membrane is controlled by two ubiquitin-like protein
conjugation pathways, ATG12-ATG5 and the microtubule-associated protein light chain 3phosphatidylethanolamine (LC3-PE). In the first case, E1 enzyme ATG7 and E2 ubiquitinconjugating enzyme ATG10 are responsible for conjugating ATG12 onto ATG5. This is a
prerequisite for the recruitment of Atg8 (LC3), which is catalyzed and covalently conjugated
with PE in the phagophore membrane. When autophagosome formation is completed, it fuses
with lysosomes. The inner membrane of the autophagosome and the cargo contained in the
autophagosome are then degraded by lysosomal hydrolases (Denton, Nicolson, & Kumar, 2012).
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Figure 1.1 Overview of autophagy.
Schematic depicting the main autophagic pathways. Briefly, the induction of autophagy is mediated by
the ULK1, VPS34, and ATG12-ATG5-ATG16 complexes. The formation mechanisms are described in
the text.

1.4.2

ULK1

Autophagosome biogenesis is a dynamic membrane event, which is executed by the
sequential function of ATG proteins. ULK1 (UNC-51-like kinase 1), the mammalian orthologue
of the yeast ATG1 (autophagy-related 1), is the serine-threonine kinase and the autophagy
initiator. Under nutrient-deficient condition, ULK1 is phosphorylated by AMPK, thereby
activating autophagy. However, under over-nutrition conditions, activated mTOR phosphorylates
ULK1 at multiple residues. The phosphorylation of ULK1 by mTORC1 results in suppression of
autophagy initiation. Thus, ULK1 is the decisive hub for autophagy regulation in response to the
metabolic stress (Kim et al., 2011).
ULK1 is also involved in hypoxia-induced mitophagy, a major mechanism involved in
mitochondrial quality control via selectively removing damaged or unwanted mitochondria.
Hypoxia activates AMPK, which in turn phosphorylates ULK1 at ser555 and promotes the

RUNNING HEAD
23
translocation of ULK1 to mitochondria and initiating mitophagy (Tian et al., 2015). Particularly,
ULK1 engages in hydrogen peroxidase-induced non-apoptosis cell death by translocating to the
nucleus and phosphorylating DNA damage repair protein poly (ADP-ribose) polymerase 1
(PARP1) (Joshi et al., 2016). Functioning as a serine/threonine kinase, ULK1 not only regulates
glucose metabolism by phosphorylating glycolytic enzymes including hexokinase,
phosphofructokinase 1, enolase 1, and the gluconeogenic enzyme fructose-1,6-bisphosphatase,
but also mediates NADPH production by regulating pentose phosphate pathway (PPP) (T. Y. Li
et al., 2016). Furthermore, ULK1 regulates ferritin turnover independent of autophagy (Goodwin
et al., 2017). Dysregulation of ULK1 has been observed in many pathological conditions. For
example, in transverse aortic constriction mouse model, ULK1activates mitophagy by a
mechanism independent of ATG5/ATG7 in the myocardial ischemic stage of myocardial
infarction, which enables selective removal of dysfunctional mitochondria. In obesity mouse
model, ULK1 is down-regulated in the hearts, and ULK1-dependent mitophagy plays a critical
role in maintaining cardiac function (D. F. Egan et al., 2011). However, the role of ULK1 in
endothelial dysfunction remains unknown.
1.4.3

ATG7

ATG7 is an autophagy gene encoding E1-like enzyme in the two ubiquitin-like
conjugation systems that are essential for the autophagosome biogenesis. Deficiency of ATG7
has been reported in mitochondrial dysfunction, ER stress, ROS overproduction, and inhibition
of proteins secretion (Antonucci et al., 2015; Heinitz et al., 2019; Mortensen et al., 2010; Qiao et
al., 2020; Y. Zhuang, Li, Li, Xie, & Wu, 2016). Overexpression of ATG7 activates autophagy
that removes misfolded proteins and aggregated contents in cardiomyocytes, and recovers ER
stress in autophagy-deficit hepatic cells (Pattison, Osinska, & Robbins, 2011) (L. Yang, Li, Fu,
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Calay, & Hotamisligil, 2010). It is reported that vascular density in muscular tissue is
indistinguishable between EC specific atg7 knockout mice and wild-type mice (Torisu et al.,
2013). However, microvascular density in the brain is significantly decreased (S. F. Zhuang et
al., 2017) in atg7 KO mice, indicating that ATG7 functions differently in muscle and brain
vasculature. Additionally, ATG7 expression is downregulated in aged brain, contributing to the
degeneration of neurons (Lipinski et al., 2010). However, whether ATG plays a role in
angiogenesis remains elusive.
Recently, several autophagy-independent functions of ATG7 have been described. For
example, ATG7 regulates G1-arrest by interacting with p53, and p53-mediated apoptosis is
activated under autophagy-deficient conditions (I. H. Lee et al., 2012). Although there is result
indicating that ATG7 is increased in hypoxia stimulation (J. Wu, Lei, & Yu, 2015), whether and
how ATG7 affects EC function and regulates postischemic angiogenesis are still unveiled.
1.4.4

Autophagy-independent functions of autophagy related proteins

The core autophagy machineries essential for autophagosome formation and
maturation contains more than 40 autophagy related proteins. In addition to functioning as
critical regulators of autophagy machineries, some ATG proteins also mediate autophagyindependent functions including protein secretion, endocytosis, virus replication and release, and
inflammasome activation.
Emerging evidence shows that ATGs are required for the production of inflammatory
mediators, such as IL-1β and IL-18. In adipose tissue, ATG7 deletion inhibits chemerin
secretion, which is a chemoattractant adipokine for immune cells such as dendritic cells and
macrophages, and promotes adipocyte differentiation (Heinitz et al., 2019). In mouse
ameloblasts, the epithelial cells that produce enamel, specific deletion of ATG7 prevents iron
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transportation from ameloblasts into the mature enamel, resulting in white but not yellow surface
of incisors (Sukseree et al., 2020). In addition, viruses use LC3 positive membranes to exit host
cells via exocytic pathways rather than via lysosome degradation pathway. ATG16L1 gene
mutant is found in Crohn’s disease, a common type of inflammatory bowel disease characterized
by mucosal ulceration and inflammation in ileum and abnormality in immune response to the gut
microbiota. This mutation of ATG16L1 gene leads to imbalanced cytokine production and is
linked to ER stress. Moreover, knockout of ATG16L1 promotes macrophages to generate more
IL-1β to mediate intestinal inflammation (Cadwell & Debnath, 2018; Galluzzi & Green, 2019;
Saitoh et al., 2008). Nevertheless, some questions remain: whether ATGs deficiency-inhibited
secretion is the consequences of compromised autophagy or their non-autophagic function. If the
secreted substances are enclosed in double membrane autophagosomes, and how they are
transported to the cell membrane.
1.4.5

Autophagy and angiogenesis

Angiogenesis often occurs in hypoxic environment that triggers autophagy response.
Autophagy has been implicated in many pathophysiological processes, including cancer,
metabolic diseases, neurodegenerative disorders, and cardiovascular diseases (Cheng, Ren, Hait,
& Yang, 2013). Moreover, increasing evidence suggests a controversial correlation between
angiogenesis and autophagy-that is both processes are regulated in a reciprocal fashion and
autophagy has dual roles in regulation of angiogenesis. Inhibition of autophagy by 3methyladenine (3-MA) or siRNA against autophagy related 5 (Atg5) reduces angiogenesis while
induction of autophagy by overexpression of Atg5 promotes angiogenesis (Du et al., 2012). In
the myocardium, activation of autophagy during ischemia is essential for cell survival (Furman,
2015; Hamacher-Brady et al., 2007; Matsui et al., 2008). Elevated VEGF-A in ischemic
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cardiomyocytes activates ROS-ER-initiated autophagy to trigger angiogenesis (Zou et al., 2019).
Moreover, autophagy activation by mTOR inhibitor, rapamycin, enhances angiogenesis in the
heat-denatured endothelial cells (P. Liang et al., 2018). This evidence suggests that autophagy
positively regulates angiogenesis. On the contrary, some studies show that, autophagy negatively
modulates angiogenesis. For example, mice deficient in autophagic protein Beclin1 (BECN1)
display a pro-angiogenic phenotype. Kringle 5 of human plasminogen, a potent inhibitor of
endothelial cell growth, induces autophagy and concurrently inhibits angiogenesis in absence of
nutritional stress or hypoxia (Cho, Chen, Chang, Wu, & Shi, 2013). Activation of autophagy by
Mebendazole is associated with inhibition of angiogenesis (Sung, Kim, Hong, & Joe, 2019).
Endostatin, a well-characterized endogenous inhibitor of angiogenesis can also evoke autophagy
(Nussenzweig, Verma, & Finkel, 2015).
The effects of autophagy on tumor angiogenesis also seems to be paradoxical as
inhibition of autophagy by either genetic deletion of ATG5 or chloroquine treatment has
different effects on tumor growth and angiogenesis. Blockage of autophagy by deleting ATG5
inhibits tumor growth with more chaotic and dysfunctional tumor vasculature, but does not
prevent tumor metastasis, while CQ treatment produced opposite effect, it normalizes the
vasculature, increases tissue oxygenation, and enhances medicine delivery. The results suggest
that ATG5 may regulate vessel homeostasis through its autophagy-related function. However,
CQ restrains tumor invasion and metastasis by normalization of vasculature independently of
autophagy function (Maes et al., 2014). Thus, the precise role of autophagy in angiogenesis
requires more detailed research.
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1.4.6

Autophagy and endothelial dysfunction

The link between autophagy and vascular functions has been studied in vitro and in vivo.
A basal level of autophagy is observed in laminar shear stress-stimulated ECs in human and
murine arteries, which protects vessels from atherosclerosis, because activation of laminar shear
stress fights against oxidative stress, promotes eNOS expression, and inhibits inflammation in
ECs. However, ECs exposed to low shear stress that might induce intimal thickening and
atherosclerosis development exhibit defective autophagy. In Apoe-/- mice with
defective endothelial autophagy develops more severe atherosclerosis, which may attribute to
endothelial dysfunction, immune cells infiltration, and lipid metabolism dysregulation (Guo et
al., 2014; J. X. Zhang et al., 2018)
Undermined EC autophagy reduces shear-induced NO generation by impairing EC
glucose metabolism and transportation, the compromised glycolysis inhibits purinergic pathway
and ultimately inhibits eNOS phosphorylation at S1177 and NO generation (Bharath et al.,
2017). Diabetic patients exhibit defective autophagy, inhibition of eNOS phosphorylation at
S1177 in response to insulin stimulation, and impaired endothelial function. The positive effect
of autophagy on NO production is supported by the evidence that enforced activation of
autophagy in diabetic ECs restores eNOS activity and NO production (Fetterman et al., 2016).
Cardiac reperfusion injury leads to glutathionylation of eNOS (GS-eNOS) and prolongs
the retention of GS-eNOS in cytosol, which promotes GS-eNOS degradation by CMA, and
simultaneously decreases NO production and diminishes the eNOS bioavailability. Noteworthy,
the macroautophagy is not involved in the degradation of GS-eNOS (Subramani, KundumaniSridharan, & Das, 2021). In type 2 diabetic mouse model, autophagy is suppressed, concurrent
with elevation of eNOS monomerization. The impairment of autophagy intensifies mitochondrial
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ROS generation, which adversely regulates dimerization of eNOS and suppresses NO formation
(L. Zhao et al., 2022). It is well known that various environmental stresses potentiate ROS
production, leading to oxidative stress and autophagy activation.
Extracellular oxidants or mitochondrial generated ROS directly activate lysosomal Ca2+
channel to release more Ca2+ into cytosol, which promotes TFEB nuclear translocation to
activate the expression of autophagy and lysosomal biogenesis-related genes, thereby promoting
autophagosome formation, autophagosome-lysosome fusion, and the degradation of autophagy
substrates, which would feedback to initiate autophagy to clean damaged mitochondria and ROS,
and to maintain intracellular homeostasis (X. Zhang et al., 2016).

1.5

Potential therapeutic strategies of autophagy for endothelial-related diseases
1.5.1

Potential therapeutic action of autophagy in angiogenesis

Anti-angiogenic drugs, such as bevacizumab and sunitinib, shrink tumor vascular
network and induce hypoxia, which in turn increases autophagic flux. The role of activated
autophagy in tumor development is debatable, although it generally serves as a mechanism of
tumor suppression, by maintaining genomic integrity and preventing proliferation and
inflammation. Accumulating evidence suggests that enhanced autophagy activity facilitates
tumor cells to avoid energy deficiency and contributes to the resistance to chemotherapy (Yun &
Lee, 2018). Autophagy inhibitor, hydroxychloroquine, combined with chemotherapy with
Gemcitabine/Nab-Paclitaxel significantly inhibits the development of resectable pancreatic
adenocarcinoma (Zeh et al., 2020).
However, some studies report that autophagy inhibition promotes the development of
tumors. For example, Beclin-1 is downregulated in human breast carcinoma. Overexpression of
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autophagic gene suppresses tumor growth (X. H. Liang et al., 1999). Administration of
Pelareorep, a non-enveloped dsRNA virus that selectively lyses KRAS-mutated colorectal tumors
cells, triggers tumor cell apoptosis, and inhibits tumor growth, which is associated with
autophagy induction, suggesting that pelareorep treatment together with autophagy activator may
enhance its anti-cancer effect (Jiffry et al., 2021). Moreover, autophagy-related proteins are
elevated after endocrine therapy in hormone receptor (HR)-positive breast cancer, in which
autophagy is considered as a positive signal that contributes to reducing tumor size (Ueno et al.,
2019). Thus, combination of autophagy activators with anti-angiogenesis reagents may stand an
effective strategy to inhibit tumor development (Y. Y. Li, Lam, Mak, Zheng, & Ho, 2013; Liu,
Fan, Wang, & Sun, 2016).
1.5.2

Potential therapeutic action of autophagy in diabetic complications

Previous studies show that autophagy is suppressed in diabetic mouse heart (Ouyang,
You, & Xie, 2014), alterations of autophagy genes are associated with certain cardiometabolic
traits, including blood pressure, lipid levels and proinsulin levels (Portilla-Fernandez et al.,
2019), and autophagy activation augments redox iron level by releasing ferritin-trapped iron,
which worsens anemia and glucose utilization in diabetic patients (Zacharski, Shamayeva, &
Chow, 2018). Moreover, multiple clinical studies demonstrate that inhibition of autophagy by
acetylation of Beclin1 ameliorates podocyte impairment (Xu et al., 2022; D. Yang et al., 2018).
In either HFD- or STZ-induced diabetic rat model, metformin treatment protects against acute
kidney injury by upregulating autophagy (S. Zhang, Xu, Yu, Wu, & Sui, 2017). Also,
administration of metformin prevents diabetic cardiomyopathy. Thus, understanding of
autophagy in diabetic complications will facilitate the discovery of a new therapeutic target for
the prevention and treatment of these life-threatening diabetes complications.
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2

HYPOTHESES AND SPECIFIC AIMS

Endothelial cells cover the whole vasculature and form an interface between circulating
blood and nearby tissues, which ensures optimal nutrients and oxygen delivery to organs. Thus,
endothelial dysfunction is deeply involved the pathophysiology of many disease states, including
cardiovascular disease and cancer. Autophagy is a catabolic process that degrades intracellular
components in lysosome, and functions as an essential pathway to maintain cellular homeostasis.
Recent studies reveal a role for deregulated endothelial autophagy in vascular senescence and
vascular diseases. However, many unanswered questions remain, such as what is the nonautophagic functions of autophagy proteins in endothelial homeostasis? What are the underlying
mechanisms by which ATG proteins impact endothelial function independently of their
autophagy function? Can modulating a specific autophagic gene be a potential therapeutic target
for pro-angiogenesis or anti-angiogenesis? Whether autophagy contributes to hyperglycemiainduced endothelial dysfunction? What are the mechanisms by which autophagy suppression
contributes hyperglycemia-induced endothelial dysfunction? This dissertation seeks to answer
the above questions by using biochemical, cellular, and in vivo models, and physiological and
molecular biological techniques. My hypothesis is that lack of ATG protein (such as ATG7)
inhibits ischemia-induced angiogenesis independently of its autophagy activity, and inhibition of
autophagy mediates hyperglycemia-induced endothelial dysfunction, understanding the basic
mechanisms of autophagy and ATG proteins in endothelial biology may provide novel strategies
for clinical treatment of cardiovascular disease and cancer. Two animal models are applied to
evaluate the hypothesis. One is hindlimb ligation induced angiogenesis and another one is
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3

RESULT 1: ATG7 REUGATES ANGIOGENESIS IN AN AUTOPHAGY
INDEPENDENT METHOD

Ablation of endothelial Atg7 inhibits ischemia-induced angiogenesis by upregulating Stat1
that suppresses Hif1a expression
Hongmin Yao1, Jian Li1, Zhixue Liu1, Changhan Ouyang2, Yu Qiu1, Xiaoxu Zheng1, Jing
Mu1, Zhonglin Xie1#
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3.2

Abstract
Ischemia-induced angiogenesis is critical for blood flow restoration and tissue

regeneration, but the underlying molecular mechanism is not fully understood. ATG7 (autophagy
related 7) is essential for classical degradative macroautophagy/autophagy and cell cycle
regulation. However, whether and how ATG7 influences endothelial cell (EC) function and
regulates post-ischemic angiogenesis remain unknown. Here, we showed that in mice subjected to
femoral artery ligation, EC-specific deletion of Atg7 significantly impaired angiogenesis, delayed
the recovery of blood flow reperfusion, and displayed reduction in HIF1A (hypoxia inducible
factor 1 subunit alpha) expression. In addition, in cultured human umbilical vein endothelial cells
(HUVECs), overexpression of HIF1A prevented ATG7 deficiency-reduced tube formation.
Mechanistically, we identified STAT1 (signal transducer and activator of transcription 1) as a
transcription suppressor of HIF1A and demonstrated that ablation of Atg7 upregulated STAT1 in
an autophagy independent pathway, increased STAT1 binding to HIF1A promoter, and suppressed
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HIF1A expression. Moreover, lack of ATG7 in the cytoplasm disrupted the association between
ATG7 and the transcription factor ZNF148/ZBP-89 (zinc finger protein 148) that is required for
STAT1 constitutive expression, increased the binding between ZNF148/ZBP-89 and KPNB1
(karyopherin subunit beta 1), which promoted ZNF148/ZBP-89 nuclear translocation, and
increased STAT1 expression. Finally, inhibition of STAT1 by fludarabine prevented the inhibition
of HIF1A expression, angiogenesis, and blood flow recovery in atg7 KO mice. Our work reveals
that lack of ATG7 inhibits angiogenesis by suppression of HIF1A expression through upregulation
of STAT1 independently of autophagy under ischemic conditions, and suggest new therapeutic
strategies for cancer and cardiovascular diseases.
3.3

Abbreviations:
ATG5: autophagy related 5; ATG7: autophagy related 7; atg7 KO: endothelial cell-specific

atg7 knockout; ChIP: chromatin immunoprecipitation; CQ: chloroquine; ECs: endothelial cells;
EP300: E1A binding protein p300; HEK293: human embryonic kidney 293 cells; HIF1A: hypoxia
inducible factor 1 subunit alpha; HUVECs: human umbilical vein endothelial cells; IFNG/IFN-γ:
Interferon gamma; IRF9: interferon regulatory factor 9; KPNB1: karyopherin subunit beta 1;
MAP1LC3A: microtubule associated protein 1 light chain 3 alpha; MEFs: mouse embryonic
fibroblasts; MLECs: mouse lung endothelial cells; NAC: N-acetyl-l-cysteine; NFKB1/NFκB:
nuclear factor kappa B subunit 1; PECAM1/CD31: platelet and endothelial cell adhesion molecule
1; RELA/p65: RELA proto-oncogene, NF-kB subunit; ROS: reactive oxygen species; SP1: Sp1
transcription factor; SQSTM1/p62: sequestosome 1; STAT1: signal transducer and activator of
transcription 1; ULK1: unc-51 like autophagy activating kinase 1; ulk1 KO: endothelial cellspecific ulk1 knockout; VSMCs: mouse aortic smooth muscle cells; WT: wild type;
ZNF148/Zfp148/ZBP-89: zinc finger protein 148.
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3.4

Introduction
Angiogenesis, the growth and proliferation of blood vessels from an existing vascular

network, is essential for many physiological processes, such as embryogenesis, tissue repair, and
organ regeneration (Potente, Gerhardt, & Carmeliet, 2011). This process needs to be finely
balanced, because excessive or insufficient angiogenesis contributes to a number of pathologies,
including myocardial infarction, diabetic retinopathy, rheumatoid arthritis, cancer, etc. (Folkman,
1995; Inampudi, Akintoye, Ando, & Briasoulis, 2018). The mechanisms that control angiogenesis
are regulated by several pro- and anti-angiogenic factors that are mainly stimulated by oxygen
deficiency, including VEGF (vascular endothelial growth factor) and EPO (erythropoietin)
(Melincovici et al., 2018; Zhu et al., 2010). Most transcriptional responses to oxygen
deficiency are mediated by HIFs (hypoxia-inducible factors) that control the expression of
numerous angiogenic, metabolic, and cell cycle genes (Ke & Costa, 2006; Pugh & Ratcliffe, 2003).
Accordingly, the HIF pathway is currently considered as a master regulator of angiogenesis. It is
essential to gain an accurate and deep understanding of HIF transcriptional machineries related to
angiogenesis in vascular disorders such as peripheral arterial disease, cerebral ischemia, and heart
attack.
Autophagy is an intracellular degradation system that delivers cytoplasmic constituents to
the lysosome for degradation (Rabinowitz & White, 2010; Xie, He, & Zou, 2011). Autophagy has
been implicated in many pathophysiological processes, including cancer, metabolic and
neurodegenerative disorders, cardiovascular and pulmonary diseases (Cheng et al., 2013).
Moreover, increasing evidence suggests a controversial correlation between angiogenesis and
autophagy. For example, Kringle 5 of human plasminogen, a potent inhibitor of endothelial cell
growth, induces autophagy and concurrently inhibits angiogenesis in absence of nutritional stress
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or hypoxia (Cho et al., 2013). Mice deficient in the autophagic protein BECN1/ Beclin1 display a
pro-angiogenic phenotype. Inhibition of autophagy by 3-methyladenine (3-MA) or siRNA against
Atg5 (autophagy related 5) reduces angiogenesis while induction of autophagy by overexpression
of Atg5 promotes angiogenesis (Du et al., 2012). In the myocardium, activation of autophagy
during ischemia is essential for cell survival (Furman, 2015; Hamacher-Brady et al., 2007; Matsui
et al., 2008). However, the precise role of autophagy in angiogenesis requires more detailed
research.
The molecular machinery of autophagy has been identified in both yeast and mammals,
and a number of genes encoding components of autophagy machinery, named ATG (autophagy
related), have been characterized (Mizushima, 2020; Yin et al., 2016). Among these proteins,
several core proteins, including ATG5 and ATG7, have long been believed to be essential for
autophagy (Glick, Barth, & Macleod, 2010). The absence of ATG5 leads to functional inhibition
of the autophagy machinery. Previous work has shown that endothelial-specific deficiency of
ATG5 attenuates pathological hypoxia/reoxygenation-related neovascularization through
suppression of autophagy (Sprott et al., 2019). ATG7 is required for the conjugation of ATG12 to
ATG5 as an E1-like enzyme, and is specifically involved in autophagosome formation (Komatsu
et al., 2005). Deletion of ATG7 severely impairs autophagy, leading to mitochondrial dysfunction,
endoplasmic reticulum stress, reactive oxygen species overproduction, and inhibition of protein
secretion (Antonucci et al., 2015; Heinitz et al., 2019; Mortensen et al., 2010; Qiao et al., 2020;
Torisu et al., 2013; Y. Zhuang et al., 2016). In addition, several autophagy-independent functions
of ATG7 have been described. Upon starvation, ATG7 interacts with TP53/p53 to inhibit the
expression of pro-apoptotic genes. Accordingly, Atg7 deletion increases DNA damage and
promotes apoptotic cell death (I. H. Lee et al., 2012). Another study also shows that ATG7
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represses the pro-apoptotic properties of caspase 9 (Han et al., 2014). This E1 enzymatic
independent function of ATG7 might be implicated in other pathological conditions (Mauthe &
Reggiori, 2016; Rosenfeldt et al., 2013). It is reported that under normoxic conditions, vascular
density in skeletal muscle is indistinguishable between wild-type (WT) and EC-specific atg7
knockout (atg7 KO) mice, but brain microvessel density of atg7 KO mice is significantly
decreased (Torisu et al., 2013; S. F. Zhuang et al., 2017), which is accompanied by inhibiting
nuclear translocation of NFkB subunit RELA/p65 that reduces IL6 (interleukin 6) production (S.
F. Zhuang et al., 2017). However, it is not clear whether the regulation of RELA/p65 nuclear
translocation by ATG7 is dependent or independent of autophagy. Since ATG7 is induced by
hypoxia (J. Wu et al., 2015), induction of endothelial cell apoptosis may limit unwanted
neovascularization of tumors, and prevention of endothelial cell apoptosis may improve
angiogenesis and vasculogenesis in patients with ischemia (Dimmeler & Zeiher, 2000), it is
important to understand whether and how the autophagy-independent functions of ATG7 influence
endothelial cell function and regulate post-ischemic angiogenesis.
In the current study, using a mouse hindlimb ischemia model, we show inhibition of
angiogenesis and impairment of post-ischemic blood flow recovery in EC-specific atg7 KO mice.
The loss of Atg7 reduces HIF1A expression by upregulating Stat1 in an autophagy-independent
manner. Our findings uncover a novel direct link between ATG7 and post-ischemic angiogenesis
and may lead to novel therapeutic strategies in the treatment of cancer or ischemic cardiovascular
disorders.
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3.5

Results
3.5.1

Angiogenesis is inhibited in endothelial-specific atg7 knockout mice subjected
to femoral artery ligation.

To determine the role of ATG7 in angiogenesis, we generated endothelial atg7-specific
knockout mice by mating female Atg7flox/flox mice with male Cdh5-Cre mice, and the offspring
was genotyped by PCR (Komatsu et al., 2005). The mice with genotype Atg7flox/flox/Cdh5-Cre+
were referred as to atg7 KO, and the littermates with genotype Atg7flox/flox/Cdh5-Cre- were used
as wild-type (WT) control (Figure 3.1 A). We examined ATG7 protein expression in isolated
mouse lung endothelial cells (MLECs) and mouse aortic smooth muscle cells (VSMCs) by
western blotting and found that endothelial ATG7 protein expression was abolished in atg7 KO
mice. However, deletion of endothelial Atg7 gene did not affect ATG7 protein expression in
VSMCs isolated from atg7 KO mouse aortas, confirming specific knockout of Atg7 in
endothelial cells (Figure 3.1 B). To determine the effects of endothelial Atg7 deletion on
angiogenesis in vivo, we performed femoral artery ligation in WT and atg7 KO mice at the age
of 8 to 10 weeks and monitored blood flow restoration on 1, 3, 7, 14, 21, and 28 days after
surgery by Laser Doppler Imaging (Figure 3.1 C). Four weeks post-surgery, the blood flow ratio
returned to 1.04 ± 0.14 in WT mice, however, the blood flow ratio only recovered to 0.70 ± 0.11
in atg7 KO mice (Figure 3.1 D), indicating an obvious impairment in perfusion recovery in atg7
KO mice.
We further assessed angiogenesis by immunostaining of PECAM1/CD31 (platelet and
endothelial cell adhesion molecule 1) in ischemic tissues. There was no obvious difference in the
number of PECAM1/CD31-positive capillaries surrounding the gastrocnemius muscle fibers
between atg7 KO mice and their WT littermates in sham-operated condition (Figure 3.1 E and
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F). Four weeks post ischemic insult, there was a significant increase in the number of
PECAM1/CD31-positive capillaries in WT mice. However, the increase in the PECAM1/CD31positive capillary was attenuated in atg7 KO mice (Figure 3.1 E and F). Thus, Atg7 deficiency
delayed the ischemia-induced angiogenesis in vivo.
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Figure 3.1 Endothelial Atg7 deletion impairs blood perfusion recovery and angiogenesis in
mouse ischemic hind limbs
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(A) Genotyping of WT (wild-type, Atg f/f/cdh5-) and atg7 KO (atg7 endothelial cell specific
knockout, Atg7 f/f/cdh5+) mice. (B) Western blot analysis of ATG7 in mouse lung endothelial
cells (MLECs) and arterial smooth muscle cells (VSMCs) isolated from WT and atg7 KO mice.
(C and D) Femoral artery ligation was performed on 8–10-week-old WT and atg7 KO mice.
Representative images showing blood flow reperfusion assessed by Doppler laser ultrasound
after ischemic injury (C). Blood flow was detected by laser Doppler at the indicated time points.
The ratio of ischemic/non-ischemic perfusion, N = 7 for each group. * P < 0.05, ** p < 0.01; ***
p < 0.001 (D). (E) Representative images of immunostaining for PECAM1/CD31 in
gastrocnemius muscles of mice subjected to femoral artery ligation. Scale bar: 50 µm. (F)
Quantification of immunohistochemistry staining for PECAM1/CD31. N = 6 for each group, ***
p < 0.001. (G) Representative images of immunostaining for ATG7 in gastrocnemius muscles of
mice subjected to femoral artery ligation. Scale bar: 50 µm. (H) Quantification of
immunohistochemistry staining for ATG7. N = 7 for each group, * p < 0.05, *** p < 0.001. (I)
Representative images of immunostaining for SQSTM1/p62 in gastrocnemius muscles of mice
subjected to femoral artery ligation. Scale bar: 20 µm. (J) Quantification of
immunohistochemistry staining for SQSTM1/p62. N = 5-6 for each group, ** p < 0.01, ns, not
significant.
We also determined the effect of ischemia on autophagy activity. In WT mice, femoral
artery ligation significantly increased the immunostaining intensity of ATG7 compared with
sham surgery. Deletion of Atg7 prevented femoral artery ligation-increased ATG7 protein
expression (Figure 3.1 G and H). Concomitantly, in WT mice, protein level of SQSTM1/p62
(sequestosome 1), an autophagic flux marker, was significantly lower (P < 0.05) in the femoral
artery ligation group than that in the sham-operated group. Lack of Atg7 enhanced
SQSTM1/p62 in sham-operated mice and prevented femoral artery ligation-reduced
SQSTM1/p62 protein expression (Figure 3.1 I and J), suggesting that femoral artery ligation
increases autophagic flux. Similarly, in cultured HUVECs, compared with normoxic treatment,
hypoxia upregulated ATG7 protein expression and activated autophagy, as indicated by
increased MAP1LC3A/LC3 (microtubule associated protein 1 light chain 3 alpha)II:MAP1LC3A/LC3-I ratio and decreased SQSTM1/p62 protein level (Figure 3.2 A and B).
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Figure 3.2 Hypoxia activates autophagy in cultured HUVECs and Atg7 deficiency inhibits
endothelial cell migration.
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(A and B) HUVECs were cultured in hypoxic chamber for 16 h, protein levels of HIF1A, ATG7,
SQSTM1/p62, and MAP1LC3A/LC3-II:MAP1LC3A/LC3-I were determined by western blot (A)
and densitometry (B). N = 3-4, * p < 0.05, ** p < 0.01. (C) HUVECs were transfected with siCtrl
or siATG7 for 48 h, cell migration was determined by wound healing assay. Scale bar: 500 µm.
(D) Migration area was quantified. N = 4, * p < 0.05. (E and F) HUVECs were transfected with
siCtrl or siATG7 for 24 h. Three-dimensional spheroids were generated in rat tail collagen I for
another 24 h and representative images of spheroids sprouting were analyzed. N = 27-35 spheroids,
*** p < 0.001. Scale bar: 20 µm. (G) Representative images of immunofluorescence staining for
pericyte marker DES (desmin) in WT and atg7 KO retina. (H) Quantification of DES staining.
WT = 8 retinas, atg7 KO = 7 retinas, 3-8 views were analyzed in each retina. (I) Representative
images of immunofluorescence staining for pericyte marker NG2 proteoglycan. (J) Quantification
of NG2 proteoglycan staining. WT = 7 retinas, atg7 KO = 5 retinas, 5-8 views were analyzed in
each retina. ns: no significance.
Next, we assessed the effects of Atg7 deficiency on ECs migration in vitro. Wound
healing assay showed that HUVECs transfected with ATG7 siRNA exhibited impaired migration
compared with the HUVECs transfected with control siRNA (Figure 3.2 C and D). In addition,
spheroid-sprouting assay revealed a reduction in sprout length in Atg7-deficient endothelial cells
(Figure 3.2 E and F), suggesting that ATG7 deficiency inhibits EC migration. Given that
pericytes are critically involved in angiogenic response (Kang et al., 2019), we determined
whether deletion of Atg7 affects pericyte function by immunofluorescence staining of pericyte
markers, DES (desmin) and NG2 proteoglycan, in WT and atg7 KO retinas. The staining of both
DES (Figure 3.2 G and H) and NG2 proteoglycan (Figure 3.2 I and J) was comparable between
WT and atg7 KO retinas, suggesting lack of Atg7 has no effect on pericyte coverage.
To determine whether suppression of endothelial autophagy regulates angiogenesis in
vivo, we knocked out endothelial ulk1 (unc-51 like autophagy activating kinase), an important
molecule in regulating autophagy initiation (Egan, Kim, Shaw, & Guan, 2011), to generate ulk1
endothelial cell-specific knockout (ulk1 KO) mice. Western blot analysis of ULK1 protein
expression in MLECs demonstrated that endothelial ULK1 protein expression was abolished in
ulk1 KO mice, indicating knockout of Ulk1 in endothelial cells (Figure 3.3 A). To determine the
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effect of Ulk1 deletion on autophagy, we detected protein level of SQSTM1/p62 and
MAP1LC3A/LC3-II:MAP1LC3A/LC3-I ratio. In ulk1 KO MLECs, SQSTM1/p62 protein level
was significantly (P < 0.05) increased whereas MAP1LC3A/LC3-II:MAP1LC3A/LC3-I ratio
was reduced Figure 3.3 B and C), indicating autophagic flux suppression. We then determined
the effect of autophagy suppression on angiogenesis by performing femoral artery ligation in WT
and ulk1 KO mice at the age of 8 to 10 weeks, and monitored blood flow restoration on 1, 3, 7,
14, 21, and 28 day after surgery by Laser Doppler Imaging (Figure 3.3 E). Four weeks postsurgery, the blood flow ratios were comparable between WT and ulk1 KO mice (Figure 3.3 D),
indicating that suppression of autophagy by ulk1 deletion had no significant effect on perfusion
recovery.
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Figure 3.3 Endothelial Ulk1 deletion has no effect on blood perfusion recovery in mouse ischemic
hind limbs.
(A) Western blot analysis of ULK1 in mouse lung endothelial cells (MLECs) isolated from WT
and ulk1 KO mice. (B) Western blot analysis of MAP1LC3A/LC3-II:MAP1LC3A/LC3-I and
SQSTM1/p62 expression in MLECs isolated from WT and ulk1 KO mice. (C) Quantification of
protein levels of MAP1LC3A/LC3-II:MAP1LC3A/LC3-I and SQSTM1/p62. N = 3-6, * p <
0.05. (D) Femoral artery ligation was performed on 8–10-week-old WT and ulk1 KO mice.
Blood flow was detected by Laser Doppler Imaging at the indicated time points. The ratio of
ischemic/non-ischemic perfusion, N = 5-6 for each group. (E) Representative images showing
blood flow reperfusion assessed by Laser Doppler Imaging after ischemic injury.
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3.5.2

Lack of ATG7 inhibits HIF1A expression and tube formation.

Given that HIF1A is a key modulator of the transcriptional response to hypoxic stress and
plays a critical protective role in ischemic cardiovascular diseases by regulating angiogenesis and
vascular remodeling (Semenza, 2014), we detected HIF1A expression using
immunohistochemistry in gastrocnemius muscles of WT and atg7 KO mice subjected to femoral
artery ligation (Fig. 2A). The result showed that the ligation significantly increased HIF1A
expression in ischemic limbs of WT mice, while the ligation failed to upregulate HIF1A
expression in atg7 KO mice (Figure 3.4 A and B), suggesting that Atg7-deficiency inhibits
ischemia-induced HIF1A expression. We further investigated whether hypoxia regulates HIF1A
expression in MLECs isolated from WT and atg7 KO mice. Deletion of Atg7 significantly
reduced Hif1a mRNA expression (Figure 3.4 C), and hypoxia increased HIF1A protein level in
WT MLECs, whereas the hypoxia-induced HIF1A expression was attenuated in atg7 KO
MLECs (Figure 3.4 D and E). Similarly, treatment of MLECs with cobalt chloride (CoCl2), a
well-known hypoxia mimetic mediator (Ciafre, Niola, Giorda, Farace, & Caporossi, 2007; Dai et
al., 2008), increased HIF1A expression in WT MLECs, and deletion of Atg7 lessened the CoCl2upregulated HIF1A expression (Figure 3.4 F and G). Similar results were observed in HUVECs
transfected with control siRNA (siCtrl) or ATG7 siRNA (siATG7) (Figure 3.5 A, B, C and D).
However, overexpression of ATG7 did not influence HIF1A expression in both normoxic and
hypoxic conditions (Figure 3.5 E and F). Notably, ATG7 deficiency did not prevent hypoxiaupregulated HIF2A protein expression (Figure 3.5 G and H). Since HIF1A is an early response
gene (Bartoszewska et al., 2015), we examined HIF1A mRNA expression in HUVECs
transfected with siCtrl or siATG7 at 30, 60, and 120 min after exposure to hypoxia. The results
showed that ATG7 deficiency depressed hypoxia-induced HIF1A mRNA expression at these
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time points (Figure 3.4 H). To determine whether reduction in HIF1A mediates ATG7deficiency-inhibited angiogenesis, we analyzed tube formation in HUVECs co-transfected with
HIF1A plasmid and ATG7 siRNA. As depicted in Figure 3.4 I and J, hypoxia upregulated HIF1A
expression in siCtrl-treated cells. The transfection of HIF1A plasmid increased HIF1A in
normoxic condition and induced a further increase in HIF1A in hypoxic condition. However, in
the cells transfected with siATG7, HIF1A expression was significantly suppressed in both
normoxic and hypoxic conditions. In line with the expression of HIF1A, silencing ATG7 reduced
tube formation in both normoxic and hypoxic conditions. By contrast, overexpression of HIF1A
in ATG7-silenced cells attenuated the reduction in tube formation under both normoxic and
hypoxic conditions (Figure 3.4 K and L). These data suggest that ATG7 deficiency
downregulates HIF1A expression at the transcriptional level and inhibits angiogenesis in vitro.
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Figure 3.4 Lack of ATG7 inhibits hypoxia-induced HIF1A expression.
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(A) Representative images of immunostaining for HIF1A in gastrocnemius muscles of mice
subjected to 4-week femoral artery ligation. Scale bar: 50 µm. (B) Quantification of the HIF1A
staining area in gastrocnemius muscle. N = 6-7, * p < 0.05, ** p < 0.01. (C) Hif1a mRNA level
was determined by RT-PCR. N = 7, * p < 0.05. (D and E) MLECs were cultured in hypoxic
chamber (1% O2, 5% CO2, 94% N2) for 24 h, HIF1A protein expression was determined by
western blot (D) and densitometry (E). N = 3, *** p < 0.001. (F and G) MLECs were treated
with CoCl2 for 24 h. HIF1A protein expression was determined by western blot (F) and
densitometry (G). N = 5, * p < 0.05, *** p < 0.001. (H) HIF1A mRNA level in HUVECs
transfected with siRNA (siCtrl) or ATG7 siRNA (siATG7) was determined by RT-PCR at
indicated time points. N = 6-11, * p < 0.05, ** p < 0.01; ns, not significant. (I and J) HUVECs
were transfected with siCtrl, siATG7 and MYC-control (Ctrl) or MYC-HIF1A (HIF1A) plasmid
for 24 h and then incubated in hypoxia chamber for another 16 h. HIF1A protein expression was
analyzed by western blotting (I) and densitometry (J). N = 5, *** p < 0.001. (K) Representative
images of tube formation assay from three independent experiments. Scale bar: 500 μm. (L)
Quantitative analysis of the number of sprouts. N = 15 fields, ** p < 0.01, *** p < 0.001.
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Figure 3.5 ATG7 deficiency inhibits hypoxia-induced HIF1A expression, but has no impact on
HIF2A expression.
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(A and B) HUVECs were transfected with siCtrl or siATG7 for 24 h, and then incubated in
hypoxic chamber (1% O2, 5% CO2, 94% N2) for another 16 h. HIF1A protein expression was
analyzed by western blot. N = 4, ** p < 0.01, *** p < 0.001. (C and D) HUVECs were
transfected with siCtrl or siATG7 for 24 h and treated with vehicle or CoCl2 for another 16 h.
ATG7 and HIF1A protein expression was measured by western blot and densitometric analysis.
N = 4, *** p < 0.001. (E and F) HUVECs were transfected with Ctrl or ATG7 (MYC-ATG7)
plasmid for 24 h, and then incubated in hypoxic chamber for another 16 h. ATG7 and HIF1A
protein expression was measured by western blot and densitometric analysis. N = 4, ns, not
significant. (G and H) HUVECs were transfected with siCtrl or siATG7 for 24 h, and then
incubated in hypoxic chamber for another 16 h. ATG7 and HIF2A protein expression was
measured by western blot and densitometric analysis. N = 9, ns, not significant. (I)
Overexpression of STAT1 inhibits HIF1A expression in hypoxic conditions. HUVECs were
transfected with STAT1 (Flag-STAT1) or control (Ctrl) plasmid for 24 h, and then treated with
vehicle or CoCl2 for another 16 h. Protein levels of STAT1 and HIF1A were determined by
western blot. (J) Quantitative analysis of HIF1A protein levels. N = 5, *** p < 0.001.
3.5.3

Upregulation of STAT1 inhibits HIF1A expression in ATG7-deficient
conditions.

Increasing evidence shows that HIF1A expression can be regulated at the mRNA level by
transcription factors under hypoxic conditions (Galban & Gorospe, 2009). Transcription factors,
such as the ISGF3 (interferon stimulated gene factor 3) complex, which is composed of STAT1,
STAT2, IRF9 (interferon regulatory factor 9), STAT3, NFKB1/NFκB (nuclear factor kappa B
subunit 1), NRF1 (nuclear respiratory factor 1), and BCLAF1 (BCL2 associated transcription
factor 1), can bind to the HIF1A gene promoter to regulate HIF1A transcription (Gerber & Pober,
2008; Koyasu, Kobayashi, Goto, Hiraoka, & Harada, 2018; Park et al., 2017; Rius et al., 2008;
Wen et al., 2019). Therefore, we identified the potential transcriptional factors that mediate the
inhibition of HIF1A expression in ATG7-deficient condition by analyzing the expression of the
six transcriptional factor genes using RT-PCR. In siATG7-transfected HUVECs, STAT1 mRNA
had the highest expression with an increase of 13.3 folds, and that was followed by the increase
in IRF9 gene expression (4.8 folds). However, silencing ATG7 did not affect the expression of
STAT3, NFKB1/NFκB, NRF1, and BCLAF1 genes (Figure 3.6 A).
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To determine whether STAT1 engages in ATG7-deficiency-inhibited HIF1A expression,
we first silenced both ATG7 and STAT1 in HUVECs and assessed HIF1A mRNA expression in
normoxic condition. We found that silencing ATG7 reduced HIF1A mRNA expression, and
STAT1 knockdown enhanced HIF1A mRNA expression as compared with siCtrl and prevented
the reduction in HIF1A mRNA expression in siATG7-transfected HUVECs (Figure 3.6 B). We
further assessed the effect of STAT1 on ATG7 deficiency-reduced HIF1A expression in
normoxic and hypoxic conditions. The results demonstrated that hypoxia increased HIF1A
protein expression, silencing ATG7 attenuated hypoxia-enhanced HIF1A protein level, and ATG7
deficiency-induced HIF1A reduction was prevented by silencing STAT1 (Figure 3.6 C and D).
Conversely, transfecting a plasmid encoding STAT1 significantly suppressed HIF1A mRNA
expression and attenuated hypoxia-upregulated HIF1A protein expression (Figure 3.6 E, F and
G). Similarly, treatment of HUVECs with CoCl2 to induce hypoxia increased HIF1A protein
level in the cells treated with control plasmid, and the increase in HIF1A protein expression was
attenuated by overexpression of STAT1 (Figure 3.5 I and J).
To determine that STAT1 mediates the transcriptional regulation of HIF1A by ATG7, we
tested whether ATG7 affects STAT1 binding to the HIF1A gene promoter in HUVECs.
Chromatin immunoprecipitation (ChIP) assay showed that silencing ATG7 significantly
increased STAT1 binding to the HIF1A promotor in both normoxic and hypoxic conditions
(Figure 3.6 H and I). Taken together, upregulation of STAT1 mediates the negative regulation of
HIF1A in ATG7-deficient endothelial cells.
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Figure 3.6 Upregulation of STAT1 inhibits HIF1A expression in ATG7-deficient conditions.
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(A) Expression of genes related to HIF1A expression, including STAT1, STAT3, NFKB1/NFκB,
IRF9, NRF1, BCALF1 was determined by RT-PCR in control and ATG7-deficient HUVECs, N
= 5, *** p < 0.001. (B) HUVECs were transfected with siCtrl, siATG7, STAT1 siRNA (siSTAT1),
or siATG7 and siSTAT1 for 48 h, HIF1A mRNA expression was determined by RT-PCR. N = 8,
* p < 0.05, *** p < 0.001. (C) HUVECs were transfected with siCtrl, siATG7, siSTAT1, or
siATG7 and siSTAT1 for 24 h, and then incubated in hypoxic chamber for another 16 h. HIF1A
protein level was measured by western blot. (D) Densitometric analysis of the western blots. N =
4, ** p < 0.01, ns, not significant. (E) HUVECs were transfected with Flag-control (Ctrl) or
Flag-STAT1 (STAT1) plasmid for 24 h, and then incubated in hypoxia chamber for another 16
h. Protein levels of STAT1 and HIF1A were determined by western blot. (F) Quantitative
analysis of HIF1A protein levels. N = 6, * p < 0.05, *** p < 0.001. (G) HUVECs were
transfected with STAT1 or Ctrl plasmid for 24 h, HIF1A mRNA was determined by RT-PCR. N
= 4, * p < 0.05. (H and I) HUVECs were transfected with siCtrl or siATG7 for 48 h and followed
by hypoxia stimulation for 1 h. ChIP analysis was performed to determine the association of
STAT1 and HIF1A promoter region. (H) RT-PCR products were analyzed by ethidium bromidestained gel analysis. (I) RT-PCR quantitative analysis. N = 4, * p < 0.05, ** p < 0.01.
3.5.4

Loss of ATG7 increases STAT1 expression and inhibits tube formation.

As silencing STAT1 significantly mitigated the reduction of HIF1A expression in ATG7deficient condition, we explored the mechanism by which ATG7 modulates STAT1 expression.
As demonstrated in Figure 3.7 A and B, deletion of Atg7 increased SQSTM1/p62 protein level
and reduced the conversion of MAP1LC3A/LC3-I to MAP1LC3A/LC3-II in MLECs. Similar
results were also found in HUVECs transfected with siATG7 (Figure 3.8 A, B, and C). In
addition, treating MLECs with chloroquine (CQ) to inhibit lysosomal enzyme activity
significantly increased MAP1LC3A/LC3-II:MAP1LC3A /LC3-I level in WT MLECs but the
effect was prevented in atg7 KO MLECs, suggesting that lack of Atg7 completely blocked the
conversion of MAP1LC3A/LC3-I to MAP1LC3A/LC3-II (Figure 3.7 C and D). The deletion of
Atg7 also significantly upregulated Stat1 mRNA (Figure 3.7 E), and increased STAT1 protein
level and phosphorylation of STAT1 at tyrosine 701 (Y701) (p-STAT1) (Figure 3.7 F and G),
but did not affect the protein levels of p-STAT6, p-STAT3, and p-STAT5 (Figure 3.7 H and I).
Also, silencing ATG7 in HUVECs upregulated STAT1 mRNA expression (Figure 3.8 D), and
increased STAT1 and p-STAT1 protein levels (Figure 3.8 E, F, G and H), but had no effect on
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protein expression of STAT3, p-STAT3, STAT5, p-STAT5, and STAT6 (Figure 3.8 4I). To
determine whether the regulatory effect of ATG7 on STAT1 is dependent on its role in
regulating autophagy, we silenced ULK1, a key initiator of mammalian autophagy (D. Egan et
al., 2011), and observed a significant suppression of autophagy, as indicted by increased
SQSTM1/p62 and reduced the ratio of MAP1LC3A/LC3-II:MAP1LC3A /LC3-I (Figure 3.7 J
and K). However, suppression of autophagy by silencing ULK1 did not increase protein levels of
STAT1 and p-STAT1 (Figure 3.7 L and M). Similarly, inhibition of autophagy by either
silencing SQSTM1/p62 (Figure 3.9 A and B) or administrating CQ had no effect on STAT1 and
p-STAT1 expression (Figure 3.9 E and F). Further, inhibition of autophagy by knockout of atg5
(atg5-/-) did not upregulate Stat1 mRNA in atg5-/- mouse embryo fibroblasts (MEFs) (Figure 3.9
G). Notably, silencing Atg7 in ulk1 KO MLECs significantly upregulated STAT1 and p-STAT1
levels (Figure 3.9 H and I). Likewise, knocking down of ATG7 in HUVECs-transfected with
ULK1 siRNA increased STAT1 and p-STAT1 protein expression (Figure 3.9 J and K). These
results suggest that ATG7 deficiency upregulates STAT1 independently of autophagy activity.
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Figure 3.7 Deletion of Atg7 increases STAT1 expression but reduces tube formation
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(A) The protein levels of SQSMT1/p62 and MAP1LC3A/LC3-II:MAP1LC3A/LC3-I were
determined by western blot in MLECs isolated from WT and atg7 KO mice. (B) Densitometric
analysis of the blots. N = 3, ** p < 0.01; *** p < 0.001. (C and D) WT and atg7 KO MLECs
were treated with or without chloroquine (CQ, 3 µM) for 24 h, MAP1LC3A/LC3II:MAP1LC3A/LC3-I protein level was detected by western blot. Densitometric analysis of the
blots. N = 3, ** p < 0.01, *** p < 0.001. (E) Stat1 mRNA expression was detected by RT-PCR
in MLECs isolated from WT and atg7 KO mice. N = 4, ** p < 0.01. (F) STAT1 and phosphoSTAT1 (Y701) protein levels were measured by western blot. (G) Quantitative analysis of
STAT1 and phosphorylated STAT1 at tyrosine 701 (Y701; p-STAT1) protein expression, N = 36, ** p < 0.01, *** p < 0.001. (H) Western blot analysis of phosphorylated STAT3 at serine 727
(S727; p-STAT3), phosphorylated STAT5 at tyrosine 694 (Y694; p-STAT5), and
phosphorylated STAT6 at tyrosine 641 (Y641; p-STAT6) in MLECs from WT and atg7 KO
mice. (I) Densitometric analysis of the blots. (J) HUVECs were transfected with siCtrl, siATG7,
or ULK1 siRNA (siULK1) for 48 h, SQSMT1/p62 and MAP1LC3A/LC3-II:MAP1LC3A/LC3-I
protein levels were analyzed by western blot. (K) Quantitative analysis of the blots. N = 4-11, **
p < 0.01. (L) HUVECs were transfected with siCtrl, siATG7, or siULK1 for 48 h, levels of total
STAT1 and p-STAT1 (Y701) were measured by western blot. (M) Quantitative analysis of
STAT1 and p-STAT1 (Y701) protein expression. N = 4-9, ns, not significant. (N) HUVECs were
transfected with control and STAT1 plasmid for 24 h, protein levels of STAT1 and p-STAT1
(Y701) were detected by western blot. (O and P) HUVECs were transfected with siCtrl or
siATG7 for 48 h, and the cells were treated with vehicle or N-acetyl-l-cysteine (NAC, 1 mM) for
additional 1 h. p-STAT1 (Y701) protein expression was measured by western blot. N = 3, *** p
< 0.001, ns, not significant. (Q) Tube formation assay was performed in MLECs isolated from
WT and atg7 KO mice. Representative images selected from 4 independent experiments. Scale
bar: 1 mm. (R) Quantitative analysis of the number of sprouts. N = 12 fields, * p < 0.05.
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Figure 3.8 . Silencing of Atg7 upregulates STAT1 and inhibits tube formation in HUVECs.
(A-C) HUVECs were transfected with siCtrl or siATG7 for 48 h. The protein levels of
SQSMT1/p62 and MAP1LC3A/LC3-II:MAP1LC3A /LC3-I were determined by western blot
and densitometry. N = 3-7, ** p < 0.01. (D) STAT1 mRNA expression was detected by RTPCR, N = 5, *** p < 0.001. (E-H) ATG7, STAT1, and p-STAT1 (Y701) protein levels were
measured by western blot and densitometry. N = 3-4, *** p < 0.001. (I) Protein levels of STAT3,
p-STAT3 (S727), STAT5, p-STAT5 (Y694), and STAT6 were measured by western blot in
HUVECs transfected with siCtrl or siATG7, N = 3. (J) Tube formation assay was performed in
HUVECs transfected with siCtrl or siATG7. The representative images were selected from 3
independent experiments. Scale bar: 2 mm. (K) Quantitative analysis of sprout number, N = 22
fields, *** p < 0.001.
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Figure 3.9 Suppression of autophagy activity is not involved in increased STAT1 and reduced
tube formation by ATG7 deficiency.
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(A) HUVECs were transfected with siCtrl or siSQSTM1 for 48 h, levels of total STAT1 and pSTAT1 (Y701) were measured by western blot. (B) Quantitative analysis of STAT1 and pSTAT1 (Y701) protein expression. N = 4, ns, not significant. (C) Tube formation assay was
performed in HUVECs transfected with siCtrl or siSQSMT1. The representative results were
selected from 3 independent experiments. Scale bar: 200 μm. (D) Quantitative analysis of sprout
number, N = 13 views, ns, not significant. (E and F) HUVECs were treated with or without
chloroquine (CQ, 10 µM) for 16 h, STAT1 and p-STAT1 (Y701) protein levels were detected by
western blot. N = 5-7, ns, not significant. (G) Stat1 mRNA level was measured by RT-PCR in
wild-type (WT), atg5-/-, and atg7-/- MEFs, N = 3, *** p < 0.001, ns, not significant. (H and I)
WT and ulk1 KO MLECs were transfected with siCtrl or siAtg7, total STAT1 and p-STAT1
(Y701) levels were measured by western blot. N = 4-7, * p < 0.05, ** p < 0.01, *** p < 0.001,
ns, not significant. (J and K) HUVECs were transfected with siCtrl, siATG7, siULK1, or siATG7
and siULK1 for 48 h, total STAT1 and p-STAT1 (Y701) levels were measured by western blot.
N = 4, * p < 0.05, ** p < 0.01, *** p < 0.001, ns, not significant. (L) Tube formation assay was
performed in HUVECs transfected with siCtrl, siATG7, siULK1, or siATG7 and siULK1. The
representative results were selected from 3 independent experiments. Scale bar: 200 μm. (M)
Quantitative analysis of sprout number, N = 8-15 views, *** p < 0.0001, ns, not significant.
Given that ATG7 deficiency upregulated STAT1 protein expression, accompanied by
higher level of phosphorylated STAT1, we reasoned that overexpression of STAT1 could
increases phosphorylated STAT1. Indeed, transfection of HUVECs with STAT1 plasmid
significantly enhanced STAT1 protein level, concurrent with increased phosphorylation of
STAT1 (Figure 3.7 N). Moreover, H2O2 and/or derived reactive oxygen species (ROS) directly
activate STAT1 in cultured astrocytes (Gorina, Petegnief, Chamorro, & Planas, 2005), glia
(Gorina, Sanfeliu, Galito, Messeguer, & Planas, 2007) and in vascular smooth muscle cells
(Madamanchi, Li, Patterson, & Runge, 2001), and the absence of autophagy leads to
accumulation of ROS (Tal et al., 2009), we further examined whether inhibition of ROS prevents
STAT1 phosphorylation in ATG7-deficent condition using N-acetyl-l-cysteine (NAC), a wellknown inhibitor of ROS (Figure 3.7 O and P). The result showed that NAC had no significant
effect on STAT1 phosphorylation in ATG7-deficient HUVECs.
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ATG7 regulates brain angiogenesis via RELA/p65-dependent interleukin 6 production (S.
F. Zhuang et al., 2017), suggesting that RELA/p65 could be a link between ATG7 and STAT1,
we therefore determined whether RELA/p65 mediates ATG7 deficiency-enhanced STAT1
expression. Silencing ATG7 did not affect NFKB1/NFκB mRNA expression (Figure 3.6 A) and
failed to increase the binding between RELA/p65 and HIF1A promoter (Figure 3.10 A). In
addition, silencing Rela/p65 did not reduce protein levels of STAT1 and p-STAT1 in WT
MLECs and could not prevent the enhancement of STAT1 and p-STAT1 protein levels in atg7
KO MLECs (Figure 3.10 B, C, and D). Taken together, RELA/p65 is not involved in
upregulation of STAT1 in ATG7-deficient conditions.
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Figure 3.10 Deletion of Atg7 has no effects on NFκB expression.
(A) Chromatin immunoprecipitation (ChIP) assay was performed to analyze the interaction
between RELA/p65 and the HIF1A promoter. HUVECs were transfected with siCtrl or siATG7
for 48 h, and the chromatin was immunoprecipitated with an antibody against RELA/p65. Mouse
IgG was used as a negative control. Precipitated DNA or 2% of the chromatin input were
analyzed by PCR. (B, C, and D) WT and atg7 KO MLECs were transfected with siCtrl and
siRela for 48 h, levels of STAT1 and p-STAT1 (Y701) were measured by western blot. N = 4, **
P < 0.01, ns, not significant.

To verify the inhibitory effect of ATG7 deficiency on angiogenesis in vitro, we examined
whether Atg7 deficiency inhibits tube formation in cultured endothelial cells. Indeed, the tube
formation was inhibited in atg7 KO MLECs (Figure 3.7 Q and R) and siATG7-transfected
HUVECs (Figure 3.8 J and K), as indicated by reducing the number of sprouts. To determine
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whether ATG7 deficiency inhibits angiogenesis independently of autophagy, we examined the
effect of autophagy inhibition on tube formation in HUVECs using SQSMT1/p62 siRNA, and
found that silencing SQSMT1/p62 did not have any effect on tube formation (Figure 3.9 C and
D). Also, suppression of autophagy by silencing ULK1 did not influence tube formation in
HUVECs either. However, silencing of ATG7 inhibited tube formation in HUVECs transfected
with either siCtrl or siULK1 (Figure 3.9 L and M). These data suggest that ATG7 deficiency
inhibits angiogenesis in an autophagy-independent manner.

3.5.5

Overexpression of ATG7 has no effects on STAT1 expression and tube
formation.

Next, we determined the effects of ATG7 overexpression on STAT1 expression.
Overexpression of ATG7 by transfecting a plasmid encoding MYC-ATG7 (ATG7) increased
MAP1LC3A/LC3-II:MAP1LC3A/LC3-I ratio and reduced SQSTM1/p62 protein level,
indicating autophagy activation (Figure 3.11 A, B, and C). However, overexpression of ATG7
did not affect STAT1 and p-STAT1 (Y701) protein expression (Figure 3.11 D, E, and F).
Moreover, RT-PCR assay demonstrated that STAT1 mRNA level in the HUVECs transfected
with ATG7 plasmid was comparable with that of the HUVECs transfected with MYC-Control
plasmid (Ctrl) (Figure 3.11 G). Correspondingly, no obvious differences were observed in tube
formation between control and ATG7-overexpressed HUVECs, as indicated by the comparable
number of sprouts (Figure 3.11 H and I). These data indicate that overexpression of ATG7 does
not affect STAT1 expression although it activates autophagy, supporting that regulatory effect of
ATG7 deficiency on STAT1 is independent of autophagic process.
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Figure 3.11 Overexpression of ATG7 does not affect STAT1 protein expression and tube
formation.
(A) HUVECs were transfected with MYC-control (Ctrl) or MYC-ATG7 (ATG7) plasmid for 24 h.
(B and C) SQSMT1/p62 and MAP1LC3A/LC3-II:MAP1LC3A/LC3-I protein expression was
measured by western blot. Densitometric analysis of the blots, N = 4-5, ** P < 0.01. (D) STAT1
and phospho-STAT1 (Y701) protein levels were analyzed by western blot. (E and F)
Densitometric analysis of the blots, N = 7, ns, not significant. (G) STAT1 mRNA level was
determined in by RT-PCR. N = 4, ns, not significant. (H) Tube formation assay was performed
24 h after transfection of Ctrl or ATG7 plasmid, three independent experiments. (I) Quantitative
analysis of sprout number, N = 28 fields, ns, not significant. Scale bar: 1 mm.
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3.5.6

Suppression of STAT1 recovers the angiogenic potential in ATG7-deficient
cells.

Since ATG7 deficiency significantly elevated STAT1 expression and inhibited
angiogenesis, we tested if inhibition of STAT1 counteracts the inhibitory effects of ATG7
deficiency on angiogenesis. To this end, we administrated fludarabine, a STAT1 inhibitor (50
μM, 16 h), in siCtrl- and siATG7-treated HUVECs, and determined the phosphorylation of
STAT1 by western blot. The result indicated that fludarabine significantly suppressed
phosphorylation of STAT1 at tyrosine 701 (Figure 3.12 A and B). Next, we examined the effects
of fludarabine on tube formation in HUVECs transfected with siCtrl or siATG7, and found that
silencing ATG7 reduced the number of sprouts, and the reduction in tube formation was
attenuated by fludarabine treatment (Figure 3.12 C and D). We further determined whether
inhibition of STAT1 attenuates the inhibitory effect of ATG7 deficiency on tube formation by
co-transfecting HUVECs with ATG7 and STAT1 siRNAs (Figure 3.12 E and F). We observed
that the co-transfection of STAT1 siRNA and ATG7 siRNA restored tube formation as compared
with the transfection of siATG7 (Figure 3.12G and H). The results suggest that STAT1
upregulation may mediate the inhibitory effect of ATG7-deficiency on angiogenesis in vitro.
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Figure 3.12 Suppression of STAT1 recovers the potential of tube formation in HUVECs.
(A-D) HUVECs were transfected with siCtrl or siATG7 and treated with STAT1 inhibitor,
fludarabine phosphate (Fluda, 50 μM) for 24 h. (A) Total STAT1 and p-STAT1 (Y701) protein
levels were measured by western blot. (B) Densitometric analysis of p-STAT1 (Y701), N = 4, *
p < 0.05, ** p < 0.01. (C) Tube formation assay was performed after the treatment. Scale bar: 1
mm. (D) Quantification of the number of sprouts. Three independent experiments. N = 13-22
fields, ** p < 0.01, *** p < 0.001. (E-H) HUVECs were transfected with siCtrl, siATG7,
siSTAT1, or siATG7 and siSTAT1. (E) Protein levels of ATG7 and STAT1 were determined by
western blot. (F) The quantification analysis of the blots. N = 4, * p < 0.05, ** p < 0.01. (G)
Tube formation assay was performed after the treatment. Scale bar: 1 mm. (H) Quantification of
the number of sprouts. Three independent experiments. N = 14-16 fields, *** p < 0.001.
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3.5.7

ATG7 deficiency promotes ZNF148/ZBP-89 nuclear translocation, increasing
STAT1 expression.

Given that ZNF148/ZBP-89 (zinc finger protein 148, protein encoded by the
human ZNF148 or mouse Zfp148 locus) is required for constitutive STAT1 expression (Bai &
Merchant, 2003), we determined whether ZNF148/ZBP-89 is involved in ATG7 regulating
STAT1 expression by detecting STAT1 expression in HUVECs transfected with control siRNA
(siCtrl) or ZNF148 siRNA (siZNF148). Transfection of ZNF148 siRNA downregulated STAT1
mRNA expression, and reduced STAT1 and p-STAT1 protein levels (Figure 3.13 A and B).
To address whether ATG7 interacts with ZNF148/ZBP-89 to regulate STAT1 expression,
we examined the subcellular distribution of ATG7 and ZNF148/ZBP-89 in WT and atg7 KO
MLECs by immunofluorescence staining. In WT MLECs, ATG7 and ZNF148/ZBP-89 were
mainly present in the cytosol, in which some ATG7 staining was colocalized with ZNF148/ZBP89 staining. However, no colocalization of ATG7 and ZNF148/ZBP-89 staining was observed in
the nucleus. The cytosol ZNF148/ZBP-89 immunofluorescence intensity was significantly lower
in atg7 KO MLECs, as compared with that of WT MLECs. However, nuclear ZNF148/ZBP-89
immunofluorescence intensity was higher in atg7 KO MLECs than that in WT MLECs (Figure
3.13 C and D). Consistently, western blot analysis of ZNF148/ZBP-89 expression in subcellular
fractions verified that ZNF148/ZBP-89 protein level in cytosol fraction was higher in WT
MLECs relative to that of atg7 KO MLECs, while nuclear ZNF148/ZBP-89 protein level in WT
MLECs was lower than that in atg7 KO MLECs (Figure 3.13 E, F, and G), suggesting that lack
of ATG7 promotes ZNF148/ZBP-89 nuclear translocation. Similar result was also observed in
HUVECs transfected with siCtrl and siATG7 (Figure 3.14 A and B). However, deletion of Atg7
had no effect on Zfp148 mRNA expression in MLECs (Figure 3.13 H). We reasoned that ATG7-
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deficiency reduces the association of ATG7 and ZNF148/ZBP-89, which promotes
ZNF148/ZBP-89 nuclear translocation and upregulates STAT1 expression. Thus, we
investigated whether ATG7 directly associates with ZNF148/ZBP-89. Immunoprecipitation of
ATG7 followed by western blotting of ZNF148/ZBP-89 showed that ATG7 indeed physically
associated with ZNF148/ZBP-89 (Figure 3.13 I and J). We further examined the effect of
silencing ZNF148 on STAT1 mRNA expression in HUVECs transfected with either siCtrl or
siATG7. In ATG7-deficient HUVECs, silencing ATG7 significantly increased STAT1 mRNA
expression, and the increase in STAT1 mRNA was abolished by silencing ZNF148 (Figure 3.13
K).
By contrast, overexpression of ATG7 did not alter ZNF148/ZBP-89 nuclear translocation
manifested by immunofluorescence staining and western blot analysis of subcellular fractions in
HUVECs (Figure 3.14 C, D, E, F, and G). Taken together, these data reveal that lack of ATG7
reduces its association with ZNF148/ZBP-89, increases ZNF148/ZBP-89 nuclear translocation,
and upregulates STAT1 expression.
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Figure 3.13 Lack of ATG7 increases ZNF148/ZBP-89 nuclear translocation and STAT1
expression
(A) Western blot analysis of STAT1, p-STAT1 (Y701), and ZNF148/ZBP-89 in HUVECs
transfected with siCtrl or ZNF148 siRNA (siZNF148). (B) STAT1 mRNA level was analyzed by
RT-PCR. N = 3, *** p < 0.001. (C and D) Representative images of immunofluorescence
staining of ZNF148/ZBP-89 (C). Quantitative analysis of immunofluorescence intensity of
ZNF148/ZBP-89. Four independent experiments. N = 37-39 cells, *** p < 0.001 (D). (E)
ZNF148/ZBP-89 protein expression was measured by western blot in whole cell lysates (W),
cytosol (C), and nuclear (N) fractions in MLECs isolated form WT and atg7 KO mice. (F and G)
Quantitative analysis of nuclear ZNF148/ZBP-89 protein levels in cell fractions, N = 4, * p <
0.05. (H) Zfp148 mRNA level was detected by RT-PCT in WT and atg7 KO MLECs. N = 5; ns,
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not significant. (I and J) The interaction between ATG7 and ZNF148/ZBP-89 was detected by
immunoprecipitation (IP) and western blot (IB). N = 3. (K) HUVECs were transfected with
siCtrl, siATG7, siZNF148, or siATG7 and siZNF148 for 48 h. STAT1 mRNA level was measured
by RT-PCR. N = 4, *** p < 0.001.
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Figure 3.14 Lack of ATG7 increases ZNF148/ZBP-89 nuclear translocation and STAT1
expression
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(A) Western blot analysis of STAT1, p-STAT1 (Y701), and ZNF148/ZBP-89 in HUVECs
transfected with siCtrl or ZNF148 siRNA (siZNF148). (B) STAT1 mRNA level was analyzed by
RT-PCR. N = 3, *** p < 0.001. (C and D) Representative images of immunofluorescence
staining of ZNF148/ZBP-89 (C). Quantitative analysis of immunofluorescence intensity of
ZNF148/ZBP-89. Four independent experiments. N = 37-39 cells, *** p < 0.001 (D). (E)
ZNF148/ZBP-89 protein expression was measured by western blot in whole cell lysates (W),
cytosol (C), and nuclear (N) fractions in MLECs isolated form WT and atg7 KO mice. (F and G)
Quantitative analysis of nuclear ZNF148/ZBP-89 protein levels in cell fractions, N = 4, * p <
0.05. (H) Zfp148 mRNA level was detected by RT-PCT in WT and atg7 KO MLECs. N = 5; ns,
not significant. (I and J) The interaction between ATG7 and ZNF148/ZBP-89 was detected by
immunoprecipitation (IP) and western blot (IB). N = 3. (K) HUVECs were transfected with
siCtrl, siATG7, siZNF148, or siATG7 and siZNF148 for 48 h. STAT1 mRNA level was measured
by RT-PCR. N = 4, *** p < 0.001.
3.5.8

Identification of binding domain between ATG7 and ZNF148/ZBP-89.

Since ZNF148/ZBP-89 is reported to regulate target genes by interacting with p53 (Bai &
Merchant, 2001), SP1 (Sp1 transcription factor), EP300 (E1A binding protein p300) (Merchant,
Bai, & Okada, 2003), and STAT3 (Y. Wu, Diab, Zhang, Izmailova, & Zehner, 2004), we
determined whether ATG7 interacts with these proteins in HUVECs. The immunoprecipitation
and western blot demonstrated that ATG7 did not interact with these proteins in HUVECs
(Figure 3.15 A and B), and there was no interaction between ZNF148/ZBP-89 and p53 (Figure
3.15 C). To identify the region of ZNF148/ZBP-89 interacting with ATG7, we generated
ZNF148 truncations fused with GST (Fig. S7H), overexpressed the truncations in human
embryonic kidney 293 (HEK293) cells, and co-transfected the cells with MYC-ATG7 plasmid.
ZNF148 truncations fused with GST were pulled down by glutathione-sepharose beads. The
efficiency of overexpressing ZNF148/ZBP-89 fragments and the association of ATG7 and
ZNF148/ZBP-89 were determined by blotting GST and ATG7, respectively (Figure 3.15 D and
E). The ATG7 protein interacted with full-length ZNF148/ZBP-89 and GST- ZNF148/ZBP-89
(amino acids 169-281), but did not interacted with the N-terminal (amino acids 1-168), Cterminal (amino acids 553-794), and GST- ZNF148/ZBP-89 (amino acids 282-552) (Figure 3.15
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D and E). The results indicate that ZNF148/ZBP-89 (amino acids 169-281) is required for
ZNF148/ZBP-89 interacting with ATG7.

Figure 3.15 Lack of ATG7 increases the binding between ZNF148/ZBP-89 and KPNB1
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(A and B) Determine the potential interacting proteins with ATG7 in HUVECs. ATG7 was
immunoprecipitated by ATG7 antibody, and EP300, SP1, and STAT3 were determined by
western blotting. (C) Cell lysates were prepared from cultured HUVECs, TP53/p53 was
immunoprecipitated, and ZNF148/ZBP-89 was detected by western blot. N = 3. (D and E) HEK
293T cells were transfected with MYC-ATG7 plasmid and GST-control (GST) or GST fused with
ZNF148/ZBP-89 full length or ZNF148/ZBP-89 truncations (amino acids 1-168, 169-281, 282552, 553-794), respectively. Binding region of ZNF148/ZBP-89 on ATG7 was determined by
GST immunoprecipitation. N = 4. (F) HEK 293T cells were transfected with siCtrl or siATG7
for 48 h, the interaction of ZNF148/ZBP-89 and KPNB1 was determined by
immunoprecipitation and western blot. N = 3. (G) The interaction of ZNF148/ZBP-89 and
KPNB1 in MLECs isolated from WT and atg7 KO mice was determined by immunoprecipitation
and western blot. N = 3.
3.5.9

ATG7 deficiency enhances the binding between ZNF148/ZBP-89 and KPNB1.

Given that the transport of molecules into and out of the nucleus is mediated by the
KPNB1 superfamily (S. J. LEE ET AL., 2003), we determined whether ATG7 deficiency affects
the association of ZNF148/ZBP-89 and KPNB1 in HEK293 cells transfected with control siRNA
(siCtrl) or ATG7 siRNA (siATG7). Immunoprecipitation and western blot revealed that there was
rarely interaction between ZNF148/ZBP-89 and KPNB1 in HEK293 transfected with control
siRNA, but the association of ZNF148/ZBP-89 and KPNB1 was significantly increased in
HEK293 cells transfected with ATG7 siRNA (Figure 3.15 F). Similarly, no association between
ZNF148/ZBP-89 and KPNB1 was observed in WT MLECs, whereas the interaction of
ZNF148/ZBP-89 and KPNB1 was significantly higher in atg7 KO MLECs than that in WT
MLECs (Figure 3.15 G), suggesting that ATG7 deficiency enhances association between
ZNF148/ZBP-89 and KPNB1, which promotes ZNF148/ZBP-89 nuclear translocation.

3.5.10 Inhibition of STAT1 by fludarabine recovers blood perfusion in ischemic limbs
of atg7 KO mice.
To verify that upregulation of STAT1 inhibits HIF1A-mediated angiogenesis in Atg7deficient condition in vivo, we examined whether administration of fludarabine (100 mg/kg, i.p.,
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once every other day) in WT and atg7 KO mice can improve angiogenesis in mouse hind limb
ischemic model. Deletion of Atg7 led to an increase in p-STAT1 (Y701) protein level in both
sham-operated and ischemic groups, the increase in STAT1 phosphorylation was significantly
mitigated by fludarabine treatment (Fig. 9A and B). At the same time, downregulation of HIF1A
in atg7 KO mice was attenuated by administration of fludarabine (Fig. 9C and D). In agreement
with the alteration of HIF1A, Laser Doppler Imaging revealed that blood flow restoration in atg7
KO mice was significantly improved as compared with saline-treated atg7 KO mice (Fig. 9E
and F). In addition, reduction in PECAM-1/CD31 staining in ischemic atg7 KO mice was
abolished by administration of fludarabine (Fig. 9G and H). To validate these results, we further
determined whether silencing of Stat1 attenuates the inhibitory effect of ATG7 deficiency on
angiogenesis by transfecting WT and atg7 KO aortic rings with control siRNA or Stat1 siRNA.
Lack of Atg7 reduced sprout number and length in aortic rings. Transfection of Stat1 siRNA
prevented the reduction of sprout number and shortening of the sprout length in atg7 KO aortic
rings (Fig. S8A, B and C), confirming that STAT1 upregulation mediates the inhibitory effect of
ATG7-deficiency on angiogenesis. Taken together, inhibition of STAT1 restores HIF1A
expression and angiogenesis in Atg7-deficient conditions.
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Figure 3.16 Inhibition of STAT1 by fludarabine recovers blood flow in ischemic hind limbs of atg7
KO mice
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Femoral artery ligation was performed in 8–10-week-old WT and atg7 KO mice. Fludarabine
phosphate was administrated 1 week post ligation (100 mg/kg, i.p., once every other day). Blood
flow was detected by Laser Doppler Imaging at the indicated time points. (A)
Immunohistochemical staining of p-STAT1 (Y701) in the gastrocnemius muscular tissue. (B)
Quantification of p-STAT1 (Y701) positive staining area. N = 4-6, * p < 0.05, *** p < 0.001, ns,
not significant. (C) Western blot analysis was used to determine HIF1A protein expression in
gastrocnemius muscular tissue in WT and atg7 KO mice. (D) Densitometry analysis
quantification of western blot, the ratio of ischemic limb to sham-surgery limb, N = 7-9, * p <
0.05, ** p < 0.01. S: Sham, I: Ischemia. (E) Representative images showing blood flow
reperfusion assessed by Doppler laser ultrasound after ischemic injury. (F) The ratio of
ischemic/non-ischemic perfusion, N = 4-7, ** p < 0.01. (G) Immunohistochemical staining of
PECAM1/CD31 in the gastrocnemius muscular tissue. (H) Quantitative analysis of the ratio of
PECAM1/CD31 positive staining area to muscular area, N = 4-6, ** p < 0.01; ns, not significant.

Figure 3.17 Silencing Stat1 recovers vascular sprouts in atg7 KO aortic rings.
(A) Inhibition of STAT1 by silencing Stat1 restores vascular sprouts in atg7 KO aortic rings.
Representative images of aortic ring assay. Scale bar: 50 µm. (B) Quantification of sprout number.
N = 9-16 rings. (C) Quantification of sprout length. N = 4-6 rings. ** p < 0.01, *** p < 0.001
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3.6

Discussion
ATG7 has been demonstrated to be essential for autophagosome biogenesis, but its role

in vascular biology remains largely unknown. In the present study, using EC-specific atg7 KO
mice, we found that lack of ATG7 in the cytoplasm disrupted the association between ATG7 and
transcription factor ZNF148/ZBP-89 that is required for STAT1 constitutive expression (Bai &
Merchant, 2003), increased the binding between ZNF148/ZBP-89 and KPNB1, which promoted
ZNF148/ZBP-89 nuclear translocation, and increased STAT1 expression. STAT1 bond to HIF1A
promotor and suppressed HIF1A mRNA expression, thereby preventing ischemia-induced
angiogenesis. Our results demonstrate that ATG7 deficiency is a novel suppressor of ischemiainduced angiogenesis.
Our understanding of the role of autophagy in vascular biology is relatively limited. It
seems that this intracellular process acts as a two-edged sword against various cellular insults in
ECs. For example, laminar flow promotes autophagic response in ECs, which suppresses
oxidant-induced endothelial cell death (Liu et al., 2015). Activation of autophagy protects
against senescence and apoptosis in high-glucose-induced endothelial cells (F. Chen et al., 2014).
In addition, oxidized LDL-inhibited autophagy mediates endothelial apoptosis (Zheng & Lu,
2020), loss of Atg7 promotes endothelial-to-mesenchymal transition and up-regulates key genes
involved in TGF-β signaling and fibrosis. (Singh et al., 2015). However, autophagy has also
been recognized as a cell death pathway in mammalian systems. Therefore, further researches
are needed for comprehensively understanding the role of autophagy in endothelial biology and
angiogenesis. Previous studies have shown that inhibition of autophagy by 3-methyladenine or
silencing ATG5 suppresses angiogenesis in aortic endothelial cells (Du et al., 2012). Deletion of
endothelial Atg7 results in lower microvessel density in the brain (S. F. Zhuang et al., 2017), but

RUNNING HEAD
78
does not affect the vascular density in skeletal muscle and retina (Torisu et al., 2013). In
addition, endothelial Atg7 deficiency promotes cutaneous wound healing, but does not affect
angiogenesis in the injured skin (K. C. Li et al., 2020; H. J. Wang et al., 2018). These data
suggest that Atg7 deficiency may have less impact on angiogenesis in physiological and some
pathological conditions. Nevertheless, it is reported that endothelial Atg7 deletion attenuates
ischemia/reperfusion-induced acute cerebral injury and inflammatory response by inhibiting proinflammatory cytokines through RELA/p65-dependent transcriptional regulation (K. C. Li et al.,
2020; H. J. Wang et al., 2018). Although decreased microvessel density in atg7-/- mouse brain is
associated with reducing interleukin 6 production through inhibiting RELA/p65 nuclear
translocation (S. F. Zhuang et al., 2017), it is not clear if RELA/p65 mediates ATG7 deficiencyenhanced STAT1 expression and whether ATG7 regulating RELA/p65 nuclear translocation is
dependent or independent of autophagy. Our study provided compelling evidence demonstrating
that Atg7 deficiency significantly inhibited ischemia-induced angiogenesis by activating STAT1inhibited HIF1A expression that initiated angiogenesis by sensing environmental oxygen
concentration and promoting growth factor transcription: 1) Atg7 deficiency delayed blood
perfusion recovery and impaired ischemia-induced angiogenesis in hind limb ischemic model. 2)
Deletion of Atg7 promoted STAT1 expression and negatively regulated tube formation. 3) Lack
of Atg7 upregulated STAT1 that inhibited HIF1A expression. 4) Silencing STAT1 recovered the
tube formation in cultured Atg7-deficient ECs. 5) Consistent with the observation that
fludarabine attenuates cerebral ischemic injury by reducing cell apoptosis (Q. Xu et al., 2015),
inhibition of STAT1 by fludarabine prevented Atg7-ablation-inhibited HIF1A expression, and
promoted blood perfusion recovery and angiogenesis in hind limb ischemic model. Our results
demonstrate that RELA/p65 is not involved in ATG7 deficiency-upregulated STAT1, and
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uncovers three previously undescribed regulatory mechanisms linked to inhibition of ischemic
angiogenesis in ATG7-deficient conditions—that is, STAT1 is a transcriptional inhibitor of
HIF1A, loss of ATG7 reduces HIF1A expression by upregulating STAT1, and ATG7 regulates
STAT1 protein expression in an autophagy-independent manner: lack of ATG7 in the cytoplasm
disrupts the association between ATG7 and transcription factor ZNF148/ZBP-89, increases the
binding between ZNF148/ZBP-89 and KPNB1, which promotes ZNF148/ZBP-89 nuclear
translocation, and increases STAT1 expression. Together, these findings establish a previously
undescribed mechanism that lack of ATG7 inhibits angiogenesis by suppression of HIF1A
expression through upregulation of STAT1 independently of autophagy under ischemic
conditions.
HIF1A is not only regulated at the protein level by post-translational modifications and
degradation, but also regulated at transcriptional level by transcription factors (Galban &
Gorospe, 2009; Gerber & Pober, 2008; Koyasu et al., 2018; Park et al., 2017; Rius et al., 2008;
Wen et al., 2019). By screening six reported HIF1A transcription factors, we found that the most
significantly increased gene was STAT1 in ATG7-deficient cells. Currently, the precise role of
STAT1 in regulating HIF1A expression remains controversial in the literature. For example, in
human aortic valve interstitial cells, the combination of IFNG/IFN-γ (interferon gamma) and
lipopolysaccharide (LPS) promotes HIF1A induction, and silencing Stat1 inhibits HIF1A protein
induction (Parra-Izquierdo et al., 2019), indicating that STAT1 is the upstream signaling required
for HIF1A expression. By contrast, in human glioblastoma cell lines, IFNG/IFN-γ suppresses the
HIF1-dependent gene transcription and silencing Stat1 abolishes the inhibitory effect of
IFNG/IFN-γ on hypoxia-induced reporter gene activity (Hiroi, Mori, Sakaeda, Shimada, &
Ohmori, 2009), suggesting that IFNG/IFN-γ-activated STAT1 functions as a negative
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transcriptional regulator of HIF1A. Our study showed that silencing Stat1 mitigated Atg7
deficiency-inhibited HIF1A expression at both mRNA and protein levels, and silencing ATG7
significantly increased STAT1 binding to the HIF1A promotor and inhibited HIF1A
transcription, indicating that loss of ATG7 reduces HIF1A expression by upregulating STAT1.
Another finding of this study is that ATG7 regulated STAT1 expression in an autophagyindependent manner. We found that ATG7 deficiency enhanced Stat1 mRNA and protein
expression, concurrent with autophagy suppression. However, suppression of autophagy by
silencing ULK1, knock down of SQSMT1, or administration of CQ failed to increase STAT1
expression. Moreover, silencing Atg7 in Ulk1-deficient ECs, in which autophagic flux was
inhibited, significantly upregulated STAT1 level. Overexpression of ATG7 to promote autophagy
had no obvious impact on STAT1 expression, indicating that inactivation of autophagy does not
upregulate STAT1 expression, and ATG7 deficiency enhances STAT1 expression in autophagydefective cells. Similar to our finding, Atg5 or Atg7 depletion is reported to increase total and
phosphorylated STAT1 by downregulating ATF3 (activating transcription factor 3) (E. Kong,
Kim, & Kim, 2020). On the contrary, another group reports that STAT1 expression is lower
in atg5 KO MEFs and the Atg5 deficiency inhibits IFNG/IFN-γ-induced STAT1
phosphorylation, suggesting that IFNG/IFN-γ autophagy-dependently induces STAT1 activation
(Chang et al., 2010). Moreover, the regulatory effects of ATG7 on STAT1 may vary in diverse
cell types. For example, in murine alveolar macrophage cell line, ATG7 deficiency impairs
STAT1 activation as P. aeruginosa stimulation, but does not affect STAT1 protein expression
(X. Li, Ye, Zhou, Huang, & Wu, 2015). In Michigan Cancer Foundation-7 (MCF7) cells, ATG7
deficiency upregulates STAT1 protein expression (Ambjorn et al., 2013) (Schwartz-Roberts et
al., 2015). However, these reports do not investigate the mechanisms by which ATG7 regulates
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STAT1 expression. To bridge this gap, our study reveals a new mechanism by which ATG7
deficiency upregulates STAT1 expression at transcriptional level via an autophagy independent
pathway.
Interestingly, we observed that loss of ATG7 reduced angiogenesis in vivo, and inhibited
tube formation in cultured ECs. However, overexpression of ATG7 had no significant impact on
the tube formation. This may be explained by the facts that STAT1 is a transcription factor that
suppresses HIF1A expression, and the interaction of ZNF148/ZBP-89 with ATG7 and KPNB1
regulates the nuclear translocation of ZNF148/ZBP-89. Our study showed that ZNF148/ZBP-89
contained a binding region of ATG7, which was required for ATG7 physically associating with
ZNF148/ZBP-89. Under basal conditions, there was rarely association between ZNF148/ZBP-89
and KPNB1, but the interaction of ZNF148/ZBP-89 and KPNB1 was significantly increased in
ATG7-deficient conditions. In MLECs, both ATG7 and ZNF148/ZBP-89 was present in the
cytoplasm, and the association of ATG7 and ZNF148/ZBP-89 was observed in the cytoplasm but
not in the nucleus. In atg7 KO MLECs, cytosolic ZNF148/ZBP-89 was significantly reduced,
while nuclear ZNF148/ZBP-89 was dramatically increased, which was concurrent with the
upregulation of STAT1. By contrast, overexpression of ATG7 did not alter ZNF148/ZBP-89
nuclear translocation and STAT1 expression. These data suggest that under basic conditions,
most ZNF148/ZBP-89 is anchored in the cytoplasm due to its binding to ATG7, which
dissociates ZNF148/ZBP-89 from KPNB1, thus only small amount of ZNF148/ZBP-89 is able
to enter the nucleus to maintain basic STAT1 expression. Although overexpression of ATG7
increases ATG7 expression, it does not significantly increase the association of ZNF148/ZBP-89
and ATG7, thus failing to reduce the nuclear translocation of ZNF148/ZBP-89 and STAT1
expression. However, under ATG7-deficient conditions, lack of ATG7 disrupts the association of
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ATG7 and ZNF148/ZBP-89. ZNF148/ZBP-89 is released from the ATG7-ZNF148/ZBP-89
complex and binds to KPNB1 that transports ZNF148/ZBP-89 from the cytoplasm to the
nucleus, where ZNF148/ZBP-89 binds to STAT1 gene promoter and upregulates STAT1
expression, leading to inhibition of HIF1A expression and angiogenesis.
Our findings may lead to improvements for the clinical cares of patients with tumor or
ischemic cardiovascular diseases. Since angiogenesis has been characterized as an essential
process for tumor cell proliferation and viability, our results that deletion of ATG7 can suppress
angiogenesis suggest that inactivation of ATG7 is sufficient to inhibit tumor angiogenesis and
suggest new clinical strategies to block tumor growth. Additionally, we found that inhibition of
STAT1 by genetic or pharmacological means prevents inhibitory effects of ATG7 deficiency on
ischemia-induced angiogenesis. This finding suggests that STAT1 inhibition may be a potential
therapeutic target for the treatment of ischemic cardiovascular diseases.
In conclusion, Atg7 deficiency impairs angiogenesis and delays blood flow reperfusion
under ischemic conditions. Lack of Atg7 upregulates STAT1 that transcriptionally inhibits HIF1A
expression, thus impairing post-ischemic angiogenesis. Our studies uncover a new molecular
mechanism for the negative effect of Atg7 deficiency on angiogenesis and demonstrate that lack
of ATG7 inhibits angiogenesis by suppression of HIF1A expression through upregulation of
STAT1 independently of autophagy under ischemic conditions. Our findings may suggest new
therapeutic strategies for cancer and cardiovascular disorders.
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3.7

Materials and Methods
3.7.1

Reagents

Antibodies and reagents were purchased from the indicated companies. ATG7 (Cell
Signaling Technology 8558), APG7 (B-9; Santa Cruz Biotechnology, sc-376212),
MAP1LC3A/B (Cell Signaling Technology, 4108), EP300 (Cell Signaling Technology, 54062S),
SQSTM1/p62 (Abcam, 56416), STAT1 (Cell Signaling Technology, 9172), p-STAT1 (Y701;
Cell Signaling Technology, 9167), STAT3 (Cell Signaling Technology, 9139), p-STAT3 (S727;
Cell Signaling Technology, 9136), STAT5 (Cell Signaling Technology, 9363), p-STAT5 (Y694)
(Cell Signaling Technology, 9359), STAT6 (Cell Signaling Technology, 5397), p-STAT6
(Y641) (Cell Signaling Technology, 9361), HIF1A (Cell Signaling Technology, 36169), HIF1A
(Santa Cruz Biotechnology, sc-13515), HIF2A (Cell Signaling Technology, 7096), ULK1 (Cell
Signaling Technology, 8054), PECAM1/CD31 (Cell Signaling Technology, 77699),
ZNF148/ZBP-89 (Santa Cruz Biotechnology, sc-137171), ZNF148/ZBP-89 (GeneTex,
GTX104894) ACTB/β-actin (Santa Cruz Biotechnology, sc-47778), GAPDH (Santa Cruz
Biotechnology, sc-32233), TUBA/α-Tubulin (Cell Signaling Technology, 3873), LMNA/lamin
A/C (Cell Signaling Technology, 4777), LMNB1/lamin b1 (Cell Signaling Technology, 12586).
SP1 (Santa Cruz Biotechnology, sc-59TRITC), TP53/p53 (Cell Signaling Technology, 2527S),
GST (Cell Signaling Technology, 2624S), KPNB1/Importin β (proteintech, 10077-1-AP),
SQSTM1 (proteintech, 18420-1-AP), NFκB RELA/p65 (Cell Signaling Technology, 4764S),
mouse secondary antibody (Cell Signaling Technology, 7076), rabbit secondary antibody (Cell
Signaling Technology, 7074), donkey anti-mouse IgG conjugated to Alexa Fluor 488 green
(ThermoFisher Scientific, 21202), donkey anti-rabbit IgG conjugated to Alexa Fluor 488 green
(ThermoFisher Scientific, 21206), goat anti-mouse IgG conjugated to Alexa Fluor 555 red
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(ThermoFisher Scientific, 21422), goat anti-rabbit IgG conjugated to Alexa Fluor 555 red
(ThermoFisher Scientific, 21428). EnVision® + Dual Link System-HRP (DAB+) (Dako
Cytomation, 3468). ATG7 siRNA (Cell Signaling Technology, 6604), ATG7 siRNA (Thermo
Fisher Scientific, 135754), STAT1 siRNA (Cell Signaling Technology, 6331), STAT1 siRNA
(Thermo Fisher Scientific, VHS40871), Stat1 siRNA (Thermo Fisher Scientific, 151007),
ZNF148/ZBP-89 siRNA (Santa Cruz Biotechnology, sc-38639), SQSTM1 siRNA (human) (Santa
Cruz Biotechnology, sc-29679), Nfκb Rela/p65 siRNA (mouse; Santa Cruz Biotechnology, sc29411), Atg7 siRNA (Santa Cruz Biotechnology, sc-41448). ULK1 siRNA (Santa Cruz
Biotechnology, sc-44182) for ex vivo transfection. The siRNA delivery reagent Lipofectamine
RNAiMAX (ThermoFisher Scientific, 13778-150), Lipofectamine® 2000 (ThermoFisher
Scientific, 11668-019). Matrigel (Corning, 356237), fludarabine phosphate (Sigma-Aldrich,
1272204), chloroquine diphosphate salt (Sigma-Aldrich, C-6628), Pierce™ ECL Western
Blotting Substrate (ThermoFisher Scientific, 32106). Stat1 alpha Flag pRc/CMV was a gift from
Jim Darnell (Addgene, 8691); pCAG-HIF1 alpha was a gift from Connie Cepko (Addgene,
21101); ATG7 plasmid was obtained as a gift from Dr. Zhixue Liu (Georgia State University),
ZNF148 plasmid (GenScript, OHu09001).

3.7.2

Mouse model of hind limb ischemia

Wild-type (WT, C57BL/6J, stock number 000664), Ulk1flox/flox (Stock number 017916),
and vascular endothelial Cdh5 (cadherin 5)-Cre mice (006137) were obtained from the Jackson
Laboratory. Atg7flox/flox mice were purchased from RIKEN BioResource Research Center
(RBRC02759). We generated atg7-EC-specific knockout mice (atg7 KO, Atg7flox/flox/Cdh5-Cre+)
by mating female Atg7flox/flox mice with male Cdh5-Cre mice to generate heterozygous mice
(atg7/f/wt:Cre/wt mice). Next, we assigned heterozygous breeding pairs to obtain homozygous
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mice. We PCR genotyped offspring using DNA from tail-snip biopsies. The mouse genotypes
were determined using following primers: Atg7 forward primer:
TGGCTGCTACTTCTGCAATGATGT, reverse primer:
CAGGACAGAGACCATCAGCTCCAC. Cdh5 transgene forward:
AGGCAGCTCACAAAGGAACAAT; transgene reverse: TCGTTGCAT CGACCGGTAA;
internal positive control forward, CTAGGCCACAGAATTGAAAGATCT; internal positive
control reverse, GTAGGTGGAAATTCTAGCATCATCC. We selected two groups of mice for
this study: (a) EC atg7 KO (atg7 KO) mice with genotype Atg7flox/flox/Cdh5-Cre+ and (b)
littermate control mice (WT) with genotype Atg7flox/flox/Cdh5-Cre-. We used 8 to 10-week-old
male mice for the experiment. Mice were housed in temperature-controlled cages under a 12-h
light-dark cycle and given free access to water and normal chow.

Mouse hind limb ischemia was induced as described previously (Niiyama, Huang,
Rollins, & Cooke, 2009) . Briefly, the left femoral artery was exposed under a dissection
microscope. The left common iliac and femoral arteries were ligated with 6-0 sutures. A sham
procedure, in which the arteries were isolated but not ligated, was performed on the contralateral
leg (Q. Lu et al., 2018). Blood flow was measured by Laser Doppler Imaging (Moor Instruments,
Devon, UK). Ischemic and non-ischemic limb perfusion was measured before and directly after
surgery, and then at 7, 14, 21, and 28 days after surgery. Image analysis software (PimSoft;
Moor Instruments, Devon, UK) was used to calculate the limb mean flux units, and the final
blood flow values were expressed as the ratio of ischemic to non-ischemic hind limb perfusion.

RUNNING HEAD
86
To examine the effect of STAT1-specific inhibitor, fludarabine phosphate, on Atg7deficiency- induced inhibition of angiogenesis, one-week post-surgery we treated atg7 KO and
WT mice with fludarabine phosphate (100 mg/kg, i.p.) or vehicle once every other day as
described previously (He, Li, Viollet, Zou, & Xie, 2015). After treatment, blood flow of hind
limbs was measured by Laser Doppler Imaging. The animal protocol was approved by the
Institutional Animal Care and Use Committee at Georgia State University. All experiment were
carried out in compliance with IACUC.

3.7.3

Cell culture

HUVECs were obtained from the American Type Culture Collection (PCS-100–013) and
grown in EBM medium (Lonza Bioscience, CC-3121), which was supplemented with
endothelial cell growth supplement (Lonza Bioscience, CC-4133) and 5% fetal bovine serum
(Sigma-Aldrich, 12303) in total. All culture media were supplemented with penicillin (100
Units/ml) and streptomycin (100 μg/ml; ThermoFisher Scientific, 15140-122). HUVECs were
used between passages four to six. For pharmacological inhibition of STAT1, HUVECs were
treated with fludarabine phosphate (50 nM) for 16 h.

3.7.4

Mouse lung endothelial cells isolation

Mouse lung endothelial cells (MLECs) were isolated as previously described (Sobczak,
Dargatz, & Chrzanowska-Wodnicka, 2010). Mouse lung was excised and cut minced finely.
Tissue was digested by type II collagenase (Worthington Biochemical, LS004177) at 37°C for
45 min, and followed by aspirating the tissue into a 20 ml syringe with 14 g cannula to get single
cell suspension. Pulmonary endothelial cells were purified by anti-PECAM1/CD31 antibody
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(BD Biosciences, 553369) conjugated magnetic beads (ThermoFisher Scientific, 11041) and
anti-ICAM2 antibody (BD Biosciences, 553325) conjugated magnetic beads, sequentially.
MLECs were grown and maintained in EBM medium (Lonza Bioscience, CC-3121)
supplemented with endothelial cell growth supplement (Lonza Bioscience, CC-4133) and 20%
fetal bovine serum (Sigma-Aldrich, 12303). MLECs were used between passage two to four.
Cultured cells were incubated under standard cell culture conditions (37°C, 20% O2, 5% CO2).
To observe the effect of hypoxia, the cells were cultured under the condition of 37°C, 1% O2, 5%
CO2, 94% N2.

3.7.5

Aortic Ring assay

The procedure was performed as previous described (Baker et al., 2011). Briefly, WT and
atg7 KO mice were euthanized at 3 months of age. The aortas were isolated, the fat tissue was
cleaned, and aortas were cut into 0.5 mm aortic rings. WT and atg7 KO aortic rings were
subjected to transfection of control siRNA or Stat1 siRNA overnight. Then aortic rings were
embedded into Matrigel (Corning, 356230) and cultured in 2.5% FBS Opti-MEM containing
VEGF (vascular endothelial growth factor) (30 ng/ml; ThermoFisher Scientific, PHC9394).
Images were taken 6 days after implantation.

3.7.6

Retina staining

Retinas were isolated from WT and atg7 KO mice on postnatal day 8. Endothelial cells
were stained with isolectin GS-IB4 (1:100; ThermoFisher Scientific, I21413) and pericytes were
co-stained by either NG2 (1:100; Millipore Sigma, AB5320) or DES/desmin (1:200; Cell
Signaling Technology, 5332S).
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3.7.7

Wound healing assay

HUVECs were transfected with control siRNA or ATG7 siRNA for 48 h and the cells
were scratched with 200 µl tips, and Images were taken at indicated time points (0 and 6 h) using
an inverted microscope. The images were analyzed with the ImageJ.

3.7.8

Spheroid sprouting angiogenesis assay

The spheroid sprouting angiogenesis assay was performed following established protocol
(Tetzlaff & Fischer, 2018). Briefly, methyl cellulose stock solution was prepared by dissolving
methyl cellulose (6 g; Sigma-Aldrich, 9004-67-5) in EBM basal medium (500 ml) (Lonza, CC3121). HUVECs (the number of cells, 2000) were suspend in 1 ml 20% methyl cellulose, 5%
FBS EBM (with EGM supplements (Lonza, CC-3124) 25 µl drops of cell suspension were
pipetted on a 15-cm Petri dish using an 8-channel pipette and kept upside-down in the cell
culture incubator (37°C, 5% CO2) for 24 h. The spheroids were collected, spun down, and resuspend in 0.5 ml methyl cellulose (containing 20% FBS). The same amount of collagen (2
mg/ml; ThermoFisher Scientific, A1048301) was added to the solution of spheroids, and the
mixed solution was transferred into 24-well plate and kept in cell culture incubator for 30 min to
allow the collagen gel to polymerize. Finally, 200 µl cell culture medium was added to the mix
solution and cultured for another 24 h in cell culture incubator (37°C, 5% CO2). The spheroids
were fixed by 10% formalin and pictures were taken by inverted microscope.
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3.7.9

Constructs of truncations of ZNF148

Truncations of ZNF148 were generated by PCR using the corresponding primers.
ZNF148 (1-168 bp): Forward 5’-GTGTCGACCATGAACATTGACGACAAACTGGAAG-3’,
Reverse 5’-ATGCGGCCGCTTAAGGGGTTTTCAAACCAAGTGATC-3’, ZNF148 (169-281):
Forward 5’- GTGTCGACCATGAAATCTCACGTTTGTGAGCACTG-3’, Reverse 5’ATGCGGCCGCTTAGTCATGATTTTCATGGCACATACG-3’, ZNF148 (282-552): Forward
5’- GTGTCGACCATGAAAAAACTAAATAGATGTGCCATCAAAG-3’, Reverse 5’ATGCGGCCGCTTAAGCTTTGTGGGAATAATGATCC-3’, ZNF148 (553-794): Forward 5’GTGTCGACCATGAATGGACAGCATGAGATATCCTTC-3’, Reverse 5’ATGCGGCCGCTTAGCCAAAAGTCTGGCCAG-3’. The fragments of ZNF148 were
constructed into PRK5-GST plasmid with Sal-I and Not-I restriction enzyme. All the constructs
were confirmed by DNA sequencing.

3.7.10 Plasmid and siRNA transfection
To overexpress ATG7, STAT1, or HIF1A, HUVECs were transfected with ATG7 plasmid
(MYC-ATG7), STAT1 plasmid (Flag-STAT1), HIF1A plasmid (MYC-HIF1A), or empty plasmid
(Ctrl) in OPTI-MEM reduced-serum media (ThermoFisher Scientific, 31985) by using
Lipofectamine 2000 (ThermoFisher Scientific, 11668019) for 24 h. To silence ATG7, STAT1,
ULK1 or ZNF148/Zfp148/ZBP-89, HUVECs or MLECs were transfected with Atg7 siRNA,
Stat1 siRNA, ZNF148/Zfp148/ZBP-89 siRNA, or control siRNA in OPTI-MEM reduced-serum
media using Lipofectamine RNAiMax transfection reagent (ThermoFisher Scientific, 13778150)
for 48 h. The transfection efficiencies of the siRNAs and plasmids were determined by western
blot analysis of target protein expression.
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3.7.11 Immunohistochemistry and immunofluorescence staining
Skeletal muscle was isolated, fixed in 4% paraformaldehyde, embedded in paraffin, and
cut into 4 μm sections. The sections were deparaffinized, rehydrated, and heated in citrate buffer
to unmask the antigens. Muscular sections were incubated with primary antibodies against
PECAM-1/CD31, p-STAT1 (Y701), or HIF1A overnight at 4°C, respectively. After rinsing in
PBS (Millipore Sigma, D5652-50L) 3 times, sections were incubated with a horseradish
peroxidase-labeled polymer detection system (DAKO EnvisionCDual link, K4061) and stained
with DAB chromogen (DAKO, K3468).

HUVECs or MLECs were fixed with -20°C methanol (Fisher Scientific, 67-56-1) and
permeabilized using 0.2% Triton X-100 (Sigma-Aldrich, T8787). Cells were blocked by goat
serum (Fisher Scientific, HK112-9K) for 30 min and incubated with corresponding primary
antibody at 4°C, overnight. The cells were washed with 0.5% Tween-20 (Sigma-Aldrich, P1379)
in PBS 3 times, then incubated with fluorescent secondary antibody for 1 h at room temperature,
and mounted with DAPI (Sigma-Aldrich, D9564). Images were recorded using an Olympus
fluorescence microscope (Olympus BX53, Tokyo, Japan) and quantified using Image-Pro Plus
6.0 (Media Cybernetics, Rockville, MD).

3.7.12 Immunoprecipitation and western blot analysis
Proteins were extracted from skeletal muscles, HUVECs, and MLECs using RIPA lysis
buffer (Santa Cruz Biotechnology, sc-24948A). Protein content was determined using the
bicinchoninic acid protein (BCA) assay reagent (ThermoFisher Scientific, 23223, 23224). For
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immunoprecipitation, proteins (500 μg for each sample) were incubated with anti-ATG7
antibody or Rabbit IgG overnight at 4°C. Protein A sepharose beads (Sigma Aldrich, GE 170780-01) were added and rotated at 4°C for 3 h. The sepharose beads were washed 5 times with
lysis buffer and subjected to western blot analysis. For western blot analysis, 30 mg of protein
were resolved by SDS-PAGE, transferred to nitrocellulose membranes (Bio-Rad Laboratories,
1620112), and probed with specific antibodies. The signals were visualized using the ECL
(ThermoFisher Scientific, 32106) detection system. The intensity of individual bands was
measured by Image J and the background was subtracted from the calculated area.
To determine the location of ATG7 binding domain on ZNF148, HEK 293T cell were
transfected with glutathione S-transferase (GST)-tagged ZNF148 truncations or GST-control
plasmid, and co-transfected with MYC-ATG7 plasmid. Cell lysates were obtained 24 h after
transfection. GST was pulled down by glutathione-sepharose beads (Sigma-Aldrich, GE17-075601), and the overexpression efficacy and the interaction of ZNF148/ZBP-89 and ATG7 were
determined by blotting GST and ATG7 antibody, respectively.

3.7.13 RNA Extraction and quantitative Real-Time (qRT)-PCR analysis
Total mRNA was extracted from cultured cells with Trizol reagent (ThermoFisher
Scientific, 15596018). For reverse transcription, 1 µg of the total mRNA was converted to first
strand complementary DNA in a 20 µL reaction volume using a cDNA synthesis Kit (Bio-Rad
Laboratories, 1708891). PCR primers used for amplification of genes were as follows:
Stat1 (mouse): forward 5’-GCTGCCTATGATGTCTCGTTT -3’, reverse 5’TGCTTTTCCGTATGTTGTGCT-3’; STAT1 (human): forward 5’-
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AGGAAAAGCAAGCGTAATCTTCA-3’; reverse 5’-TATTCCCCGACTGAGCCTGAT-3’;
GAPDH (human): forward 5’-CATCAATGGAAATCCCAT-3’; reverse 5’TTCTCCATGGTGGTGAAGAC-3’; HIF1A (human): forward 5’TCCAAGAAGCCCTAACGTGT-3’; reverse 5’-TTTCGCTTTCTCTGAGCATTCTG-3’;
NEAT1 (human): forward 5’-GTTCCGTGCTTCCTCTTCTG-3’; reverse 5’GTGTCCTCCGACTTTACCAG-3’; IRF9 (human): forward 5’GCCCTACAAGGTGTATCAGTTG-3’; reverse 5’-TGCTGTCGCTTTGATGGTACT-3’;
BCLAF1 (human): forward 5’-CCGCGATTCGGCGTGTCAGG-3’; reverse 5’GACCCATTTCTTTTCTCCTTGGTT-3’; NRF1 (human): forward 5’AGGAACACGGAGTGACCCAA-3’; 5’-TATGCTCGGTGTAAGTAGCCA-3’; Hif1a (mouse):
forward 5’-CCTGCACTGAATCAAGAGGTTGC-3’; reverse 5’CCATCAGAAGGACTTGCTGGCT-3’; Zfp148 (mouse): forward 5’GAGATTTCCTTCAGCGTTTAC-3’; reverse 5’-TTTGGAAGGGTCTGGTTGTC-3’; β-actin
(mouse): forward 5’-GGCTGTATTCCCCTCCATCG-3’; reverse 5’CCAGTTGGTAACAATGCCATGT-3’. All samples were run in duplicate and underwent initial
denaturation at 95°C for 5 min, followed by 40 rounds of amplification (95°C for 30 s, 60°C for
30 s) using iQTM SYBR® Green Supermix (Bio-Rad Laboratories, 1708884) and the CFX96TM
Real-Time System (Bio-Rad Laboratories). All data were analyzed using the 2-ΔΔCT method and
normalized with GADPH or Actb as described previously (Mu, Zhang, Tian, Xie, & Zou, 2020).

3.7.14 Chromatin immunoprecipitation (ChIP) assays
The ChIP assay were performed using SimpleChIP® Enzymatic Chromatin IP Kit (Cell
Signaling Technology, 9003s) according to the manufacture’s instruction. 4×106 HUVECs were
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used for each immunoprecipitation. Protein was crossed-linked to DNA by addition of 1% of
formaldehyde, and the cross-linking process was terminated by glycine. Chromatin was
sonicated to 100 to 500 bp fragments. To determine the interaction between STAT1 and HIF1A
promoter, the DNA fragments were immunoprecipitated with antibodies against STAT1 (dilution
1:50) or normal rabbit IgG (Cell Signaling Technology, 2729) overnight at 4°C. All DNA
samples were purified, and PCR was conducted to measure the relative amount of interaction
between STAT1 and HIF1A promoter. The following primers were used for the amplification:
forward: 5’-CACATCTGAGCAACGAGACCAAAGG-3’, reverse: 5’GCGCTGCTGAGAAGGGATTTC-3’. The enrichment of HIF1A gene DNA fragments was
normalized to the input of total genomic DNA for each sample. To determine the interaction
between RELA/p65 and HIF1A promoter, the DNA fragments were immunoprecipitated with
antibodies against RELA/p65 (dilution 1:50; Cell Signaling Technology, 6956S) or normal
mouse IgG (Vector Laboratories, I-2000) overnight at 4°C. All DNA samples were purified, and
PCR was conducted to measure the relative amount of interaction between RELA/p65 and
HIF1A promoter. The following primers were used for the amplification: forward: 5’GAGTTCCCCTGTGCTCCGTG-3’, reverse: 5’-TTCTCCTCGGCCTCAGTGCT-3’. The
enrichment of HIF1A gene DNA fragments was normalized to the input of total genomic DNA
for each sample.

3.7.15 Cytosol and nuclear fractionation
HUVECs or MLECs were washed with ice-cold PBS (pH7.4) twice and collected into 1.5
ml micro-centrifuge tube. The cells were lysed by adding 600 µl RIPA containing protease
cocktail. 200 ul of the lysate was collected as “whole cell lysate”. The remained 400-µl lysates
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were centrifuged for 10 s at the maximum speed of Eppendorf (Sigma Aldrich, Eppendorf
Centrifuge 5418 R). 200 µl of the supernatant was collected as “cytosolic fraction”. The pellet
was resuspended by 1 ml RIPA buffer and centrifuged for 10 s at the maximum speed of the
Eppendorf. The pellet resuspended by adding 200 µl RIPA buffer and used as “nuclear fraction”.

3.7.16 Tube formation assay
The experiment was performed as manufacture’s instruction (Corning, 356237).
HUVECs were used less than passage 5. Passage 2 of MLECs were used in this experiment.
Twenty-four-well culture plates were coated with Matrigel (280 µl/ well) according to the
manufacturer’s instructions. HUVECs were transfected with siRNA or plasmid for 24 h, and
then seeded on coated plates at 5×104 cells/well in EBM containing 10% FBS and incubated at
37°C for another 16 h under normoxic or hypoxic conditions. Tube formation was observed
using an inverted fluorescence microscope (Olympus IX73, Tokyo, Japan). Images were
captured with a video graphic system (CellSens Software, Tokyo, Japan). The degree of tube
formation was quantified by measuring the number of sprouts in three randomly chosen lowpower fields from each well using the NIH Image Program. Each experiment was repeated at
least three times.

3.7.17 Statistical analysis
Data were expressed as mean ± standard deviation (SD). One- or two-way ANOVA was
used to determine the differences among three or more groups, followed by Bonferroni post-hoc
analysis using GraphPad Prism 9 software (GraphPad Software, Inc., La Jolla, CA).
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Comparisons between 2 groups of values were assessed using the Student’s t test. P < 0.05 was
considered statistically significant.
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RESULT 2: AUTOPHAGY INHIBITION AGGREGATES T1D-INDUCED
ENDOTHELIAL DYSFUNCTION

ULK1 deficiency worsen STZ-induced endothelial dysfunction by two pipelines—elevating
ROS production and inhibiting eNOS phosphorylation
Hongmin Yao, Xiaoxu Zheng, Jian Li, Qilong Wang, Gloria Andrea Torres Rivera,
Ming-Hui Zou and Zhonglin Xie
4.1

Abstract
ULK1 is a serine/threonine kinase and involved in the initiation of autophagy, which

maintains intracellular metabolic needs by digesting intracellular materials. However, whether and
how autophagy is involved in hyperglycemia-induced endothelial dysfunction are still not fully
understood. Here, we generated endothelial-specific Ulk1 knockout (ulk1 KO) mice, treated the
mice with streptozotocin (STZ) to induce type 1 diabetic animal model, and analyzed endothelial
function, reactive oxygen species (ROS) production, and eNOS phosphorylation. We found that
STZ-induced type 1 diabetes inhibited autophagic flux and reduced protein levels of autophagy
gene related protein, including ULK1, ATG7, ATG5, and Beclin1, which was accompanied by
overproduction of ROS, inactivation of eNOS, and

impairment of acetylcholine-induced

relaxation of isolated mouse aortas. Ulk1 deletion in endothelial cells (ECs) exacerbated
endothelium-dependent vessel relaxation, intensified ROS production, and worsened eNOS
inactivation in STZ-treated mouse aorta. In addition, we determined that the overproduced ROS
was predominantly derived from mitochondria but not NOX (Nicotinamideadenine-dinucleotide
phosphate (NADPH) oxidase) system. Importantly, eNOS phosphorylation at Ser1177 was
reduced in ULK1-deficient conditions. Therefore, defective autophagy is an important event in
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diabetes-induced endothelial dysfunction. Activation of autophagy and overexpression of ULK1
may be potential strategies to prevent endothelial dysfunction in diabetes.
4.2

Introduction
Diabetes mellitus is a metabolic disease characterized by hyperglycemia resulting from

defects in insulin secretion or action. Diabetes is basically divided into two types, type 1 diabetes
is dependent on external insulin, and type 2 diabetes is characterized by insulin resistance. The
chronic hyperglycemia of diabetes is associated with endothelial dysfunction, an early event of
cardiovascular diseases. Type 1 diabetic patients exhibit abnormal glucose metabolism, ROS
overproduction, and enhanced AGEs (advanced glycation end products) products (Katsarou et al.,
2017). The endothelium is a single layer of endothelial cells (ECs) lining the entire vascular system
(Kruger-Genge et al., 2019). . Glucose enters the cells through GLUT-1 (Glucose transporter 1),
and predominantly regulated by extracellular glucose levels. Thus, endothelial cells are more
susceptible to hyperglycemia-induced damage than other cell types (Knapp, Tu, & Wu, 2019).
Autophagy is a highly conserved intracellular catabolic process for degradation of longlasting protein, protein aggregation, malfunctioned organisms, and even pathogen (He & Klionsky,
2009). It is maintained in a certain level in nutrition sufficient condition, but it is highly activated
in nutrition deprivation (Cuervo & Macian, 2012). Many reports indicate that autophagy is
impaired in hyperglycemia conditions (Niu et al., 2019; Xie et al., 2011), the role of autophagy,
however, in hyperglycemia-induced endothelial dysfunction remains elusive. In particularly,
whether high glucose inhibits or promotes autophagy is debatable, and how autophagy affects
endothelial function is still unclear.
ULK1 (unc-51-like kinase 1), the initiator of classic autophagy, is a serine/threonine
protein kinase and usually forms a large complex with ATG13 and FIP200, ATG101, which serves
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as a platform to recruit other autophagic molecules to initiate autophagy. mTORC1 (mammalian
target of rapamycin complex 1) phosphorylates ULK1 and ATG13, leading to inhibition of the
ULK1 complex; while the complex can be activated by stress conditions by disassociating
mTORC1 from the complex (Jung et al., 2009). For example, in glucose starvation condition,
ULK1 is phosphorylated by AMPK at Ser 317 and Ser 777, which prevents mTORC1phosphorylating ULK1 at Ser 757 (Kim et al., 2011). ULK1 also targets ATG4B, ATG9, ATG14L,
Beclin 1, and subunit of the PI3K complex to facilitate autophagy occurrence (Nakatogawa, 2020).
Besides the autophagy-related functions, ULK1 also regulates glycolysis since several essential
glycolytic enzymes are the substrates of ULK1 (T. Y. Li et al., 2016). However, if ULK1 is
involved in the development of endothelial dysfunction in diabetes is unknown. In the present
study, we aim to determine the role of ULK1 and autophagy in hyperglycemia-induced endothelial
dysfunction.
4.3

Results
4.3.1

Hyperglycemia reduces ATG protein expression and inhibits autophagy activity

To understand the relationship between autophagy activity and endothelial dysfunction in
diabetic conditions, we treated C57BL/6J mice with streptozotocin (STZ) to induce type 1
diabetes, and determined the effect of hyperglycemia on autophagy by analyzing ATG protein
expression in STZ-treated mouse aortas. The homogenized aortic samples were prepared and the
expression of SQSTM-1/p62, ATG7, ATG5, Beclin 1, ULK1, and the ratio of LC3-II to LC3-I
was determined by western blot. The results indicated that hyperglycemia reduced the expression
of ATG proteins, including ATG7, Beclin1, and ULK1. Concomitantly, autophagy flux was
suppressed, as evidenced by reduced conversion of LC3-I to LC3-II and increased SQSTM1/p62 protein levels. (Figure 4.1 A and B). We also verified the effect of hyperglycemia on
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autophagy in cultured human umbilical vein endothelial cells (HUVECs) and found that high
glucose significantly increased SQSTM1 protein levels and reduced the lipidated form of LC3
(LC3-II) (Figure 4.1 C and D). Blocking autophagy using chloroquine (CQ) increased both LC3II and SQSTM-1/p62 levels at both control and HG conditions (Figure 4.1 E, F and G).
Consistent with the in vivo finding that hyperglycemia inhibits ULK1 protein expression in
aortic tissues, high glucose also reduced ULK1 protein expression in cultured HUVECs (Figure
4.1 H and I). The data suggested that hyperglycemia reduces ULK1 expression and inhibits
autophagy in ECs. High glucose inactivates AMPK but has no effect on TFEB nuclear
translocation.
4.3.2

High glucose inactivates AMPK but has no effect on TFEB nuclear
translocation

The activated transcription factor EB (TFEB) enters into the nucleus to regulate the
expression of genes involved in different steps of the autophagy process (Bala & Szabo, 2018;
Napolitano & Ballabio, 2016). We therefore examined the effects of high glucose on TFEB
protein expression, and observed similar TFEB protein expression in HUVECs treated with
either normal glucose or high glucose (Figure 4.2 A). Because nuclear translocation is required
for TFEB inducing the expressions of targeted genes, we determined the subcellular distribution
of TFEB in HG condition by detecting TFEB protein levels in subcellular fractions. The TEFB
protein levels in cytosol and cellular fractions are comparable between the cells treated with
either normal glucose or high glucose (Figure 4.2 B). Previous studies show that diabetes inhibits
AMP-activated protein kinase (AMPK) activity, a central regulator of metabolism and autophagy
(Towler & Hardie, 2007). We determined the effect of high glucose on AMPK activity by
measuring the phosphorylation of AMPK at Thr172. Compared with normal glucose treatment,
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high glucose significantly reduced AMPK phosphorylation (Figure 4.2 C and D), suggesting that
HG inhibits AMPK signaling pathway but had not effect on TFEB signaling pathway in
endothelial cells.Inhibition of autophagy by endothelial-specific ulk1 knockout worsens diabetesinduced endothelial dysfunction.
4.3.3

Inhibition of autophagy by endothelial-specific ulk1 knockout worsens
diabetes-induced endothelial dysfunction

To establish the role of autophagy in the development of diabetes-induced endothelial
dysfunction, we generated endothelial-specific ulk1 deleted mice by mating ulk1flox/flox mice with
Chd5Cre mice to generate ulk1flox/flox Cdh5+ (ulk1 KO) mice and ulk1flox/flox Chd5- (WT) mice. The
ulk1flox/flox Chd5- littermate was used as wild-type (WT) control (Figure 4.3 A). Analysis of Ulk1
expression by real-time PCR indicated that Ulk1 mRNA level was abolished in ulk1 KO mouse
lung endothelial cells (MLECs) (Figure 4.3 B). Western blot analysis showed that the protein
expression of ULK1 was barely detected in MLECs of ulk1 KO mice. In contrast, ULK1
expression in aortic smooth muscle cells (SMCs) was not affected (Figure 4.3 C). Moreover,
immunohistochemistry staining of ULK1 in WT and ulk1 KO mouse aortas showed that positive
staining of ULK1 was observed in WT but not ulk1 KO mouse endothelium (Figure 4.3 D),
indicating that Ulk1 was successfully deleted in EC cells in ulk1 KO mice. As ULK1 is the
essential for autophagy initiation, we further assessed the autophagic changes in Ulk1-deficient
MLECs. Treating MLECs with chloroquine (CQ) to inhibited lysosomal enzyme activity
significantly increased LC3-II and SQSTM1 levels in both WT and ulk1 KO MLECs, suggesting
that deletion of Ulk1 prevents autophagy process (Figure 4.3 E).
We then determined the effect of autophagy suppression on endothelial function by
treating WT and ulk1 KO mice with STZ to induce type 1 diabetes. The fasting blood glucose
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assay indicated that STZ treatment significantly enhanced blood glucose in both WT and ulk1
KO mice, but deletion of Ulk1 did not affected blood glucose in either vehicle- or STZ-treated
mice (Figure 4.4). Immunohistochemistry staining of ULK1 showed that the positive staining of
ULK1 in vehicle-treated WT aortas was stronger than that in vehicle-treated ulk1 KO, STZtreated WT, and STZ-treated ulk1 KO mice (Figure 4.3 F).
Next, we tested whether autophagy contributes to endothelial dysfunction in diabetic
mice. Compared with control aortic rings, aortic rings from STZ-treated mice exhibited impaired
endothelial-dependent relaxation induced by acetylcholine (Ach). However, endotheliumdependent vasorelaxation induced by Ach was not impaired in ulk1 KO mouse aortas (Figure 4.3
G). The impairment of Ach-induced endothelium-dependent relaxation in aortic rings from ulk1
KO was more server than that in aortic rings from STZ-treated WT mice (Figure 4.3 G),
indicating that suppression of autophagy contributes to endothelial dysfunction in diabetic mice.
However, suppression of autophagy by Ulk1 deletion had no effect on endothelium-independent
vasorelaxation induced by SNP (Figure 4.3H). The above results manifest that deletion of Ulk1
to inhibit autophagy aggravates STZ-induced endothelial dysfunction.
4.3.4

Autophagy deficiency intensifies hyperglycemia-induced ROS overproduction

Reactive oxygen species (ROS) overproduction is one of the main causes of
hyperglycemia- induced endothelial dysfunction, as ROS accumulation correlates with eNOS
uncoupling and decrease the bioavailability of nitric oxide (NO) (Montezano & Touyz, 2012) . We
next detect ROS generation in aortas isolated from WT and ulk1 KO mice treated with either STZ
or vehicle by Dihydroethidium (DHE) staining. The result depicted that in WT mice, STZ
stimulation promoted ROS formation relative to vehicle injection. Deletion of ULK1 exacerbated
ROS generation in STZ-treated ulk1 KO mice although ROS production did not significantly
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increase in vehicle-treated ulk1 KO mice (Figure 4.5 A and B). Mitochondria are the major
contributor to ROS production in diabetes (J. Chen, Stimpson, Fernandez-Bueno, & Mathews,
2018; Kaludercic & Di Lisa, 2020). The absence of autophagy impairs mitochondrial functions,
leading to ROS overproduction (Roca-Agujetas et al., 2019; Thomas & Gustafsson, 2013). We
further examined the effect of defective autophagy on mitochondrial ROS production in diabetic
conditions. HUVECs transfected with ULK1 siRNA or control siRNA were treated with HG or
osmotic control (OC) for 48 h, and the cells were stained with MitoSox. The result showed that
compared to OC, silencing ULK1 significantly elevated MitoSox fluorescent intensity in control
cells. HG treatment tended to increase MitoSox fluorescence intensity in the cells transfected with
siCtrl, and induced more MitoSox fluorescence intensity in siULK1-treated cells (Figure 4.5 C
and D). The results suggest that inhibition of autophagy by silencing ULK1 augments HG-induced
mitochondrial ROS production.
4.3.5

High glucose does not influence that NADPH oxidases (NOXs) expression

Given that NADPH oxidases (NOXs) are one of the major sources of cellular ROS (Bedard
& Krause, 2007), we also tested if high glucose induced NOXs expression or enhanced their
activity. We found that hyperglycemia had no effects on NOX2 protein and mRNA expression in
STZ-treated mouse aortas. In addition, high glucose concentrations did not affect the expression
of NOX2 and NOX4 in high glucose-treated HUVECs (Figure 4.6 A-D). We next tested whether
or not components of NADPH oxidase are affected by high glucoses by western blotting for p22,
p47, and p67 phox in HUVECs. Exposing HUVECs to high glucose for 24 did not change the
expression of p22 phox, p47 phox, and p67 phox (Figure 5E-G), suggesting that NADPH may not
be involved in HG-induced ROS overproduction in endothelial cells.

RUNNING HEAD
103
4.3.6

ULK1 deficiency inhibits eNOS phosphorylation

As we found that diabetes inhibited autophagy, associated with decrease in protein level of
ULK1, a serine/threonine-specific protein kinase, and impairment of eNOS-related vessel
relaxation, we therefore investigated whether the decrease in ULK1 expression participates in the
reduction of eNOS phosphorylation at Ser1177 (p-eNOS). To this end, we measured the protein
levels of total and phosphorylated eNOS in HUVECs transfected with ULK1 siRNA or control
siRNA. The results indicated that silencing ULK1 significantly inhibited phosphorylation of eNOS
at S1177, but had no obvious impact on total eNOS protein expression (Figure 4.7 A, B and C).
In addition, immunofluorescence (IF) staining of p-eNOS in aortas isolated from WT and ulk1 KO
mice treated with either STZ or vehicle showed that STZ-treated mice expressed lower p-eNOS
protein expression in endothelium relative to vehicle-treated mice. Ulk1 deletion decreased peNOS expression and exacerbated HG-reduced p-eNOS protein level (Figure 4.7 D and E).
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Figure 4.1 Hyperglycemia inhibits autophagic flux in ECs
(A-C) Wild-type (WT; C57BL/6J) mice were treated with STZ or vehicle at 2 to 3 months of
age, and aortic tissues were collected after diabetes induction for 6 months. (A) Protein levels of
ATG7, ATG5, ULK1, Beclin1, SQSTM1 and LC3-I/LC3-II were analyzed in mouse aortic
homogenates. (B) Densitometric analysis of western blots in panel A. (C) HUVECs were treated
with normal glucose (NG; 5 mM), osmotic control (OC; 5 mM glucose + 25 mM mannitol), or
high glucose (HG; 30 mM) for indicated time. LC3-I/LC3-II and SQSTM1/p62 protein levels
were measured by western blot. (D) Densitometric analysis of SQSTM1/p62 protein levels and
the ratio of LC3-II:LC3-I. * P < 0.05, *** P < 0.001, N = 3-4. (E and F) HUVECs were treated
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osmotic control or high glucose for 72 h, and the cells were treated with CQ (10μM) or vehicle
for 16 h before collecting the samples. LC3-I:LC3-II ratio and SQSTM1/p62 protein levels were
measured by western blot (E). (F and G) Densitometric analysis of SQSTM1/p62 protein levels
and the ratio of LC3-II:LC3-I. * P < 0.05, *** P < 0.001, ns, not significant, N = 3-5. (H)
HUVECs were treated with high glucose for 72h, ULK1 protein expression was determined by
western blot. (I) Densitometric analysis of ULK1 protein levels. * P < 0.05, N = 5.

Figure 4.2 High glucose inactivates AMPK but has no effect on TFEB nuclear translocation
(A) HUVECs were treated with NG, OC, or HG for indicated time, and TFEB expression was
measured by western blot. (B) HUVECs were treated with OC or HG for 24 h. Cytosol (C) and
nuclear (N) fractions were prepared, and TFEB protein levels in the fractions were measured by
western blot. (C) WT MLECs were treated with OC or HG for 72 h, AMPK and p-AMPK
protein levels were measured by western blot. (D) Densitometry analysis of p-AMPK protein
level. * p < 0.05.
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Figure 4.3 Endothelial-specific ulk1 knockout worsens diabetes-induced endothelial dysfunction
(A) Genotyping of Ulk1flox/flox Cdh5+ (ulk1 KO) and Ulk1flox/flox Cdh5- (wild-type; WT) mice. (B)
Ulk1 mRNA level was detected by PCR in mouse lung endothelial cells (MLECs) isolated from
WT and ulk1 KO mice. (C) Western blot analysis of ULK1 protein expression in vascular
smooth muscle cells (VSMCs) and MLECs isolated from WT and ulk1 KO mice. (D)
Immunohistochemical staining of ULK1 was performed in mouse aortas collected from WT and

RUNNING HEAD
107
ulk1 KO mice. Scale bar: 50 μm. (E) MLECs obtained from WT or ulk1 KO mice were treated
with vehicle (Veh) or chloroquine (CQ; 3 µM) for 16 h. Protein levels of ULK1, SQSTM1, and
LC3-I:LC3-II ratio were detected by western blot. (F) Aortas were stained with ULK1 antibody
in WT and ulk1 KO mice treated with STZ or vehicle (Veh). (G-H) Ulk1 deficiency exacerbates
STZ-induced endothelial dysfunction. WT and ulk1 KO mice were treated with either vehicle or
STZ for 6 months. (G) Endothelium-dependent vasodilator responses were measured in the
presence of acetylcholine (Ach, 10-9 to 10-4 M). (H) Endothelium-independent vasodilator
responses were measured in the presence of sodium nitroprusside (SNP, 10-10 to 10-5 M) (H) N=
4-7. * P < 0.05, WT+Veh vs. ulk1 KO+ STZ; # P < 0.05, ulk1 KO+Veh vs. ulk1 KO+ STZ.

Figure 4.4 Blood glucose level
Fasting blood glucose determination in WT+Veh, ulk1 KO+Veh, WT+STZ and ulk1 KO +STZ
mice after STZ or Vehicle treatment for 6 months. N = 3-6.
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Figure 4.5 Ulk1 deficiency enhances ROS formation in diabetic conditions.
(A) DHE staining was performed in aortic tissues isolated from WT and ulk1 KO mice treated
with vehicle or STZ for 6 months. (B) Quantitative analysis of DHE fluorescence intensity. N =
3-8, ** P < 0.01. (C) Mitochondrial ROS production was determined by MitoSOX staining.
Scale bar: 1 mm (D) Quantitative analysis of MitoSox fluorescence intensity. N = 3-4, * P <
0.05, ** P < 0.01, *** P < 0.001.
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Figure 4.6 High glucose has no effect on NOXs expression.
(A and B) C57BL/6J mice were treated with vehicle (Veh) or STZ for 6 month, NOX2 protein
level in aortas was determined by western blot and densitometry. (C) HUVECs were treated with
NG, OC, or HG for indicated time, and NOX2 expression was measured by western blot. (D and
E) HUVECs were treated with NG, OC, or HG for 24 h, protein levels of NOX4 (D) and
p67phox (E) were measured by western blot. (F and G) HUVECs were treated with NG, OC, or
HG for 24 h, protein levels of p47phox (F) and p22phox (G) were measured by western blot.
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Figure 4.7 ULK1 deficiency inhibits eNOS phosphorylation.
(A) HUVECs were transfected with ULK1 siRNA or control siRNA for 48 h, protein levels of
ULK1, eNOS, p-eNOS were measured by western blot. (B and C) Densitometry analysis of A. N
= 8-9, ns: not significant，*** P < 0.0001. (D) Aortas were stained with p-eNOS antibody in
WT and ulk1 KO mice treated with STZ or vehicle (Veh). (E) Aortas were stained with eNOS
antibody in WT and ulk1 KO mice treated with STZ or vehicle (Veh).

4.4

Discussion
In the current study, we found that hyperglycemia impaired endothelium-dependent

vasorelaxation, which accompanied by reduced autophagy-related protein levels and inhibited
autophagic flux. Inhibition of autophagy by deletion of ULK1 worsened hyperglycemia-induced
endothelial dysfunction. Mechanistically, the hyperglycemia-induced ROS-overproduction
impaired

endothelial

function,

diabetes-reduced

ULK1

expression

inhibited

eNOS

phosphorylation. In addition, suppression of autophagy by knocking out ULK1 aggravated ROS
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overproduction, and induced a further decrease in eNOS phosphorylation, thereby exacerbating
endothelial dysfunction.
Both activation and inhibition of autophagy by hyperglycemia have been reported by
different research groups (Niu et al., 2019; Ruart et al., 2019). The controversial results prompted
us to determine the effects of hyperglycemia on endothelial autophagy activity. In this study, we
determined a wide spectrum of autophagic related proteins in endothelial cells and found that most
of them were decreased, the transformation of LC3-II from LC3-I was significantly inhibited, and
SQSTM1 protein was accumulated in diabetic conditions. These results convinced us that
autophagy was inhibited by HG stimulation. Another important evidence that HG inhibited AMPK
phosphorylation at thr172, which inhibited autophagy signaling and suppressed autophagy
activity. Since nuclear translocation of TFEB is required for the expression of genes involved in
different steps of the autophagy process, we examined if HG affect TEFB protein expression and
nuclear translocation. It seems that HG did not affect TFEB expression and subcellular
distribution. Our results suggest that HG suppresses autophagy activity via inhibition of AMPK
but not TFEB signaling. To understanding the role of deficient autophagy in hyperglycemiainduced endothelial dysfunction, we deleted endothelial Ulk1 gene to inhibit autophagy and
induced diabetes in these mice. Although endothelium-dependent vasorelaxation induced by Ach
was not impaired in ulk1 KO mouse aortas. STZ-induced endothelial dysfunction was more server
in STZ-treated ulk1 KO than STZ-treated WT mice, supporting that defective autophagy is an
important event in diabetes-induced endothelial dysfunction.
It is well known that diabetes-induced ROS overproduction is one of the main causes of
hyperglycemia-induced endothelial dysfunction. Using DHE staining of aortas, we demonstrated
that suppression of autophagy by deletion of ULK1 exacerbated hyperglycemia-induced ROS
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generation in STZ-induced diabetic mice. Consistently with that mitochondria are the major source
of ROS production, and absence of autophagy cannot efficiently remove dysfunctional
mitochondria, leading to ROS overproduction, MitoSox staining showed that HG induced more
mitochondrial ROS production in ULK1-deficient HUVECs. Notably, HG did not affect the
expression of components of NADPH oxidase, including NOX2, NOX4, p22, p47, and p67phox.
Our study indicates that autophagy deficiency aggravates diabetes-induced mitochondrial ROS
overproduction.
ULK1 is a serine/threonine protein kinase. In addition to its autophagy-related functions,
ULK1 also regulates glycolysis by directly phosphorylates several essential glycolytic enzymes
(T. Y. Li et al., 2016). In the amino acid/ serum starvation conditions, ULK1/2 phosphorylates
and potentiates hexokinase (HK) activity leading to increase in glucose uptake, meanwhile,
dampens phosphofructokinase 1 (PFK1), enolase 1(ENO1), and swerves glycolysis to pentose
phosphate pathway (PPP) pathway, which also generates reductant, NAPDH, to sustain
intracellular homeostasis (T. Y. Li et al., 2016). We provided new evidence suggesting ULK1 may
directly phosphorylate eNOS, as silencing ULK1 reduced phosphorylation of eNOS at Ser1172
without affecting eNOS protein expression, deletion of endothelial ULK1 reduced eNOS
phosphorylation in ulk1 KO endothelium and induced a further reduction in diabetic ulk1 KO mice.
Thus, further investigations are warranted to characterize the mechanism by which ULK1
influences eNOS activity.
In summary, hyperglycemia inhibits both autophagy activity and eNOS phosphorylation,
accompanied by ROS overproduction, which leads to reduction in NO bioavailability and
impairment of endothelial dependent vasorelaxation. Importantly, these effects are augments in
EC-specific ulk1 KO mice. Therefore, defective autophagy in an important event in diabetes-
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induced endothelial dysfunction. Activation of autophagy and overexpression of ULK1 may be
potential strategies to prevent endothelial dysfunction in diabetes.

4.5

Method and Materials
4.5.1

Ulk1 KO mice

Ulk1flox/flox mice in a C57BL/6J background and CreCdh5+ mice were purchased from The
Jackson Laboratory (Bar Harbor, ME). The endothelial cell-specific ulk1 knockout (ulk1f/fCdh5+;
ulk1 KO)) mice were generated by crossing female Ulk1f/fCdh5+/- with male Ulk1f/fCdh5+/- mice.
Littermate Ulk1f/fCdh5- mice were used as wild-type (WT) control. The offspring was genotype
by PCR using the primers listed in Table 4.1. All mice were C57BL/6J background, maintained
on a 12:12-h light-dark cycle at 25 °C, and given free access to water and food.
Table 4.1 Genotyping primer
Target gene
Cdh5 Trans FW
Cdh5 Trans RV
Cdh5 ctrl FW
Cdh5 ctrl RV
Ulk1 WT FW
Ulk1 WT RV
Ulk1 Mutant FW
Ulk1 Mutant RV

4.5.2

Primer sequence
AGGCAGCTCACAAAGGAACAAT
TCGTTGCAT CGACCGGTAA
CTAGGCCACAGAATTGAAAGATCT
GTAGGTGGAAATTCTAGCATCATCC
CAGTTAGGTTCACTGCAGACTTG
TTTATCCGTCTTCTGCTATTGG
CTTGGGTGGAGAGGCTATTC
AGGTGAGATGACAGGAGATC

Streptozocin (STZ)-induced type 1 diabetic mouse model

Streptozocin (STZ; Sigma Aldrich, S0130-1g) was used to induce diabetic mouse model
as previously described (Furman, 2015). The WT and ulk1 KO mice were received
intraperitoneal injections of STZat a dose of 50 mg/kg body weight (BW) for 5 constitutive days.
Blood glucose level was measured from a tail-vein blood sample using a One Touch Basic blood
glucose monitoring system 28 days after STZ stimulation. Development of diabetes was defined
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by blood glucose more than 300 mg/dL 7 days after the first injection of STZ. The animal
protocol in this study was approved by the Institutional Animal Care and Use Committee at
Georgia State University.
4.5.3

Assays of endothelium-dependent and endothelium-independent vasorelaxation

Vessel bioactivity was assessed by organ chamber as described previously. Thoracic
aortic rings (3-4 mm) were prepared and mounted in 5 ml organ baths containing Kreb’s solution
(118.3 mM NaCl, 4.7 mM KCl, 1.2 mM MgSO4, 1.2 mM KH2PO4, 2.5 mM CaCl2, 25 mM
NaHCO3, 0.026 mM EDTA, and 11 mM glucose). The organ bath was bubbled with 95% O2 and
5% CO2 gases and was maintained at 37°C. Aortic rings were equilibrated in organ bath for 15
min under a tension of 5 mN. Contractile responses of aortic rings were evoked using 30 nM
U46619 to obtain reproducible responses. At the plateau of contraction, acetylcholine (1×10-8 to
1×10-4 mol/L) or SNP (1×10-10 to 1×10-6 mol/L) was sequentially added according to
concentration gradient to the organ bath to induce endothelium-dependent or -independent
relaxation, correspondingly. The aortas were rinsed by Kreb’s solution for 10 min in each time of
reagent change.
4.5.4

Cell culture

HUVECs were obtained from the American Type Culture Collection (PCS-100-010) and
grown in EBM medium (Lonza Bioscience, CC-3121), which was supplemented with
endothelial cell growth supplement and 5% fetal bovine serum. All culture media were
supplemented with penicillin (100 Units/ml) and streptomycin (100 μg/ml). HUVECs were used
between passage four to six. Cultured cells were incubated under standard cell culture conditions
(37 °C, 20% O2, 5% CO2).
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Mouse lung endothelial cells (MLECs) were isolated as previously described (Sobczak et
al., 2010). Mouse lung was excised and minced with scissors. Tissue was digested by type II
collagenase (Worthington Biochemical, LS004177) at 37 °C for 45 min, and followed by
aspirating the tissue into a 20 ml syringe with 14 g cannula to get single cell suspension. Lung
endothelial cells were purified by anti-PECAM1/CD31 antibody conjugated magnetic beads and
anti-ICAM2 antibody conjugated magnetic beads, sequentially. MLECs were grown and
maintained in EBM medium (Lonza Bioscience, CC-3121) supplemented with endothelial cell
growth supplement (Lonza Bioscience, CC-4133) and 20% fetal bovine serum (Sigma-Aldrich,
12303). MLECs were used between passage two to four. Cultured cells were incubated under
standard cell culture conditions (37 °C, 20% O2, 5% CO2).
Aortic smooth muscle cell isolation: the mice at 8 to 10 weeks of age were sacrificed,
thoracic aortas were dissected, and the adventitia were removed. The vessels were incised
longitudinally, and the endothelial cells were gently scraped off. The aortas were then minced
into square with side length of 1-2 mm. The aorta pieces were attached to a 60-mm Patri dish
coated with FBS for 1 h and then SMCs culture medium, DMEM/F12 (Corning, 10-092-CV)
media containing 10% FBS and 1% P/S was added to the attached aorta pieces carefully. After
sub-culturing for 3 passages, the cultured cells were verified to be VSMCs by immunostaining
with anti-smooth muscle α-actin antibody, followed by counterstaining with Hoechst (Thermo
Fisher Scientific, 62249)
4.5.5

Mouse aortic homogenates preparation

Aortas were isolated from WT and ulk1 KO mice, treated with STZ or vehicle,
perivascular connective tissue was cleaned, and cut into small pieces. Aortic tissues were
homogenized in RIPA lysis buffer (Santa Cruz Biotechnology, sc-24948A). The protein-rich
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supernatant was obtained by centrifugation (12,000×g, 20 min, 4 °C). Protein concentration was
determined by bicinchoninic acid protein (BCA) assay kit (Thermo Fisher Scientific, 23225).
4.5.6

Western blot analysis

Proteins were extracted from aortas or cells by using RIPA lysis buffer (Santa Cruz
Biotechnology, sc-24948A). Protein content was determined using the BCA assay reagent,30 µg
of protein were resolved by SDS-PAGE, transferred to nitrocellulose membranes (Bio-Rad
Laboratories, 1620112), and probed with specific antibodies. The signals were visualized using
the ECL (ThermoFisher Scientific, 32106) detection system. The intensity of individual bands
was measured by ImageJ.
4.5.7

Assessment of ROS production in vivo

Fresh aorta was immersed in tissue freezing medium (O.C.T compound; VWR, 25608930), snap frozen in liquid nitrogen. Frozen sections (8

m) was incubated in PBS containing 5

M dihydroethidium (DHE) in a light-protected humidified chamber at 37°C for 30 min.
Sections were then observed under an Olympus BX-51 fluorescence microscope using the same
imaging settings in each experimental condition. Superoxide production was evaluated by
fluorescence intensity at Ex 470 and Em 580 nm.
4.5.8

Detection of mitochondrial ROS production in HUVECs

HUVECs were subjected to corresponding treatment and then incubated with 0.5 μM
MitoSox (Thermo Fisher Scientific, M36008) for 30 min. Cells were washed with sterilized PBS
solution (Millipore Sigma, D5652-50L) 3 times, and changed to normal culture medium. The
pictures were taken by inverted fluorescence microscope (Olympus IX73, Tokyo, Japan).
4.5.9

SiRNA transfection

HUVECs were transfected with ULK1 siRNA, or control siRNA in OPTI-MEM reduced-
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serum media using Lipofectamine RNAiMax transfection reagent (ThermoFisher Scientific,
13778150) for 48 h. The transfection efficiency of the siRNAs was determined by western blot
analysis of target protein expression.
4.5.10 Immunohistochemistry and immunofluorescence staining
Aorta was isolated, fixed in 4% paraformaldehyde, embedded in paraffin, and cut into 4μm sections. The sections were deparaffinized, rehydrated, and heated in citrate buffer to unmask
the antigens. Aortic sections were incubated with primary antibodies against ULK1 overnight at
4 °C. After rinsing with PBS 3 times, sections were incubated with a horseradish peroxidaselabeled polymer detection system (DAKO EnvisionCDual link, K4061) and stained with DAB
chromogen (DAKO, K3468).
Immunofluorescence staining was performed as previously described. Freshly dissected
mouse aortic tissues were embedded in Tissue-Tek OCT Compound and frozen in -80 °C. The
aortic segments were cut into 8µM. The section was immersed in -20 °C acetone for 15 min and
washed with PBS 3 times, and the sections were incubated with corresponding primary antibody
at 4°C, overnight. Then incubated with fluorescent secondary antibody for 1 h at room
temperature, and mounted with DAPI (Sigma-Aldrich, D9564). Images were recorded using an
Olympus fluorescence microscope (Olympus BX53, Tokyo, Japan) and quantified using ImagePro Plus 6.0 (Media Cybernetics, Rockville, MD).
4.5.11 Data analysis
Data were expressed as mean ± standard deviation (SD). One- or two-way ANOVA was
used to determine the differences among three or more groups, followed by Bonferroni’s posthoc analysis using GraphPad Prism 9 software (GraphPad Software, Inc., La Jolla, CA).

RUNNING HEAD
118
The Student's t test was used to compare the means between two groups. P < 0.05 was
considered statistically significant.
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5

DISCUSSION

Our findings, for the first time, revealed that lack of ATG7 inhibited ischemia-induced
angiogenesis by suppression of HIF1A expression, identified STAT1 as a suppressor of HIF1A
expression by binding to HIF1A promoter to inhibit HIF1A transcription, thereby preventing
angiogenesis, and demonstrated that ATG7 regulated STAT1 expression in an autophagyindependent manner, instead ATG7 associated with ZNF148/ZBP-89, the constitutive
transcriptional factor of STAT1, to prevent its nuclear translocation. In the absence of ATG7,
ZNF148/ZBP-89 was released from the ATG7-ZNF148/ZBP-89 complex and associated with
KPNB1, which transported ZNF148/ZBP-89 into the nucleus, where it bond to the STAT1 gene
promoter, upregulating STAT1 expression. We propose that normalizing ATG7 to potentiate
angiogenesis may prevent ischemic heart disease and peripheral artery disease, while inhibiting
ATG7 may have therapeutic effect on tumorigenesis and metastasis.
We also showed hyperglycemia or high glucose treatment inhibited autophagic activity in
ECs. Inhibition of endothelial autophagy by deletion of ULK1 exacerbated endothelial
dysfunction by reducing NO production and enhancing ROS production. In addition, eNOS
phosphorylation was significant inhibited in ULK1-deficient conditions. We also determined
that mitochondria was the prominent sources of ROS.

5.1 Defective angiogenesis and angiogenesis therapy: from the view of autophagy
Uncontrolled angiogenesis is essential for the progression of tumor and retinopathies,
while inadequate angiogenesis is critical for the development of cardiovascular disease. The
precise role of autophagy in angiogenesis under various conditions may be opposite. Autophagy
occurring at basal levels recycles cellular nutrients during stress conditions and promotes cell
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survival. Disruption of this process prevents cell survival in diverse organisms (Allen &
Baehrecke, 2020; Das, Shravage, & Baehrecke, 2012). However, autophagy also promotes cell
death in some circumstances. Inhibition of autophagy by administration of either 3-MA or ATG5
siRNA prevents angiogenesis in aortic ECs, whereas derivate of natural product magnolol
(Ery5), a potent autophagy activator, also functions as an anti-angiogenesis factor; additionally,
gold nanoparticles inhibit retinal angiogenesis by activating autophagy (Shen et al., 2018). The
elevated autophagy causes type-II programmed cell death and tumor vasculature shrink (Kumar
et al., 2013). Thus, inhibition of autophagy has potential therapeutic effects on cancer in
combined with anti-angiogenesis reagents. However, a recent study shows that inhibition of
autophagy by either genetic deletion of ATG5 or chloroquine treatment has different effects on
tumor growth and angiogenesis (Du et al., 2012; Schaaf et al., 2019). It seems that different
approaches to modulate autophagy might generate distinct effects on angiogenesis. Thus, caution
will be required when interpreting the results from studies that report the association between
manipulation of autophagy activity and angiogenesis.
Temporal function of autophagy in regulating angiogenesis should also be considered
because there might be a biphasic response in autophagy dysregulation in some pathological
conditions. Recently, a study assessing the effects of autophagy activation on cardiac function in
mouse model of anthracycline-induced cardiotoxicity (AIC) demonstrates that ATG7-based
autophagy activation improves cardiac function in late stage but has detrimental effect in the
earlier stage of AIC (Y. Wang et al., 2021). Furthermore, during the tumor development, in the
earlier stages, autophagy promotes tumorigenesis by serving as a facilitator of nutrient recycling
and remobilization, but in the later stages, autophagy functions as tumor suppressor by removing
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damaged organelle and limiting cell growth (Kardideh, Samimi, Norooznezhad, Kiani, &
Mansouri, 2019).
In the present study, we found that in normoxic conditions, loss of Atg7 downregulates
HIF1A expression, thereby inhibiting cell migration and preventing angiogenesis although it has
no effect on HIF2A expression. However, deficiency of autophagy related factor, beclin 1,
enhances hypoxia-induced angiogenesis by increase HIF2A and erythropoietin expression.
Moreover, in basal condition, deficiency of beclin 1 has no significant impact on cell migration
and proliferation (S. J. Lee, Kim, Jin, Choi, & Ryter, 2011), which are different from our
findings. It might be due to these two autophagic proteins regulate HIFs expression through
different signaling pathways. Several Studies have shown that autophagy can promote
angiogenesis, for example, autophagy is activated during the recovery of heat-denatured
endothelial cells, which is required for angiogenesis.

However, ATG7 deficiency promotes

wounded skin healing but has no significant impact on angiogenesis, this result suggests that
ATG7 possesses autophagy- independent functions, in addition to regulation of autophagosome
formation (K. C. Li et al., 2020). Notably, we found that atg7 overexpression did not promote
angiogenesis nor HIF1A expression, concurrently, there were no significant changes in STAT1
protein expression and phosphorylation. It seems that overexpress ATG7 may be potential
strategy to restore angiogenesis to normal level in ATG7-deficient diseases without inducing
excessive vessel formation (Baselli et al., 2022; Collier, Guissart, et al., 2021; Collier, Olahova,
McWilliams, & Taylor, 2021).
Our study demonstrates that ATG7 deficiency-induced STAT1 expression suppresses
HIF1A expression, but we cannot exclude that it may also activate other signaling pathways,
such as immune response, as STAT1 is a key transcription factor in IFNγ signaling, which is

RUNNING HEAD
122
involved in multiple immune system functions. Thus, our findings suggest a link between
autophagic proteins and immune response, and the deficiency of ATG7 in some pathological
conditions may provoke immune response.
ECs in tumor site are exposed to a pro-angiogenesis environment that contains high
levels of VEGF, nutrient deficiency, and hypoxia. This environment promotes ECs to release
matrix metalloproteinases that enhance angiogenesis by degradation of the vascular basement
membrane and remodeling of extracellular matrix. Most transcriptional responses to oxygen
deficiency in tumor site are mediated by HIFs (hypoxia inducible factors) that control the
expression of numerous angiogenic, metabolic, and cell cycle genes (Ke & Costa, 2006; Pugh &
Ratcliffe, 2003). Thus, upregulation of HIF-1 appears to be an essential mechanism-mediated
resistance to anti-angiogenic therapy (H. Xu et al., 2015). HIF1A can promote the generation of
angiogenic factors to escape the anti-angiogenesis treatment by specifically targeting VEGF
(Blagosklonny, 2004). HIF1A not only leads to tumor cells resistant to radiation and
chemotherapy, but also increases the chances of tumor cells invasion and metastasis and
contributes to poor prognosis (Ebos et al., 2009; Paez-Ribes et al., 2009).
Generally, autophagy is considered as protective mechanism under hypoxic conditions and
has a high correlation with chemotherapy resistance, for example, genetic or pharmacological
inhibition of autophagy sensitizes anti-angiogenic therapy in glioblastoma xenografts (Hu et al.,
2012). Thus, the efficacy of inhibition of ATG7 in preventing anti-angiogenesis therapy
resistance is worth further investigation.
Our results also suggest that overexpression of ATG7 may have prospective therapeutic
utilization in ischemic diseases, as our results show that enhancing ATG7 expression has no
significant impact on STAT1 expression and does not induce extra HIF1A expression, which can
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prevent the over neovascularization as reported in HIF1A gene treatment in ischemic disease.
Nevertheless, the effect of overexpression ATG7 on angiogenesis in ATG7-deficit condition
warrants further investigation.
5.2 Prevention of diabetes-induced endothelial dysfunction: from the view of
autophagy
NO bioavailability has high correlation with endothelial function, while ROS
overproduction induces eNOS uncoupling, leading to reduction in NO bioavailability, and has
detrimental effects on endothelial homeostasis. Autophagy is a major process in maintaining
cellular homeostasis, and is necessary to maintain redox homeostasis. However, the exact
mechanism by which autophagy regulates endothelial function in diabetic conditions remains
elusive. It has been reported that autophagy facilitates removal of damaged mitochondria and
reduces ROS production (W. Wu et al., 2015). The activation of autophagy by curcumin in ECs
protects endothelial cells from the oxidative damage (Han et al., 2012). Glycolytic inhibitor or
H2O2 induces ROS production, which in turn activates autophagic pathway to protect against
those stress stimuli and increase EC viability (Q. Wang, Liang, Shirwany, & Zou, 2011).
However, the effects of autophagy regulating NO bioavailability seems controversial.
Impairment of autophagy by silencing Atg3 in endothelial cells inhibits shear-stress-induced
increases in eNOS phosphorylation and nitric oxide bioavailability. Whereas in the HUVEC
cultured in the medium without serum, the inhibition of autophagy by chloroquine restores NO
production, reduces superoxide generation, and promotes EC proliferation (Bharath et al., 2014;
Pestana, Oishi, Salistre-Araujo, & Rodrigues, 2015). Our study shows that diabetes reduces the
expression of ATG proteins, including ULK1, a serine/threonine-specific protein kinase, and
demonstrates that ULK1 deficiency inhibits eNOS phosphorylation at Ser1177 to prevent its
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activation in diabetic conditions. However, further study is needs to determine whether ULK1
directly phosphorylates eNOS and enhances NO bioavailability.
To date, our understanding about the role of autophagy in vascular biology is relatively
limited. This catabolic intracellular process seems to be involved in both protecting and injuring
ECs in response to various stimuli. For example, laminar shear stress promotes autophagy in ECs
by activating Sirt1 and FoxO1, which induces autophagic genes expression to prevent oxidantinduced endothelial damage (Liu et al., 2015). The elevated autophagy also suppresses high
glucose-induced senescence and apoptosis in ECs (F. Chen et al., 2014). Conversely,
uncontrolled activation of endothelial autophagy promotes the development of CVD. We find
that high glucose undermines autophagy and impairs endothelial function and overexpression
ULK1 prevents NO deficiency in response to hyperglycemia and oxidative stress. Taken
together, modulating autophagy represents an attractive therapeutic target for treating CVD.
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